US-WERT vor RETTUNG - KURSCHANCE 150%! - 500 Beiträge pro Seite

[HAIRMAN2002]

SYMPHONIX DEVICES WKN 912376

Jetzt soll es also doch Investor geben - riesige Nachfrage gestern - hier noch zu 10 cents zu bekommen!

Sollten jetzt altes Hoch von 20 $cents ( vor wenigen Tagen ) toppen können!

Gruss vom
Hairman

[Miriana]

Und mir sagt man das Pushen nach....*kopfschüttel*

nee nee nee

Aber Spaß beiseite, könnte wirklich noch ein Knaller werden, mal abwarten !

Ist aber wirklich ein heißer High-Risk Wert !

Gruß
Miri

[Lipser]

[Viva-los-Tioz]

@Hairman2002

Woher sind Deine Infos?
Bitte um Fakten.

Gruß
Viva

[MikkaS]

worldcom aus im januar aus chapter11???
UAL heute nachmittag -90% zocken?oder?was?

[MilamarMOD [Mod]]

@Hairman

Die Antwort auf Frage 4 interessiert mich brennend!!!!!!

Mila

[Lipser]

@milamar

Altes Spiel von Hairman! Woher die "Fakten" kommen kann man in allen Threads von Hairmann sofort erkennen!
Eine Meldung wird zitiert und massige Annahmen dazu gedichtet und als Faktum dargestellt.
Beispiele: Infogenie (heute) oder Freenet (Schmidt ) usw.

Wie hieß es doch gleich?
...Das Verbreiten von Falschmeldungen etc. ist auch im Internet strafbar...



Lipser

[MikkaS]

@MilamarMOD

Glaube einen Ami-Wert kann man nicht Pushen

Gehand. St. Kurszeit
Nasdaq SMPX USD 0,080 0,087 + 0,007 + 8,75 1,83 Mio. 19.638.404 06. Dez 00:25
Berlin SX6 EUR 0,090 0,098 + 0,008 + 8,89 2.934 29.500

Aber hast recht,eine Quelle muss man schon bringen !!

[Miriana]

Hallo ich bin es nochmal !

Eins ist jedenfalls merkwürdig !

Warum steht der Wert bei island.com unter den TOP 5 ???

Also ich bin jedenfalls sehr sehr positiv eingestellt !

Schaut mal unter foldenden Link selber nach :

http://data.island.com/ds/data/toplist/index.jsp?symbol=SMPX

Gruß
Miri

[Viva-los-Tioz]

@Miriana

Dort stehen doch nur die Werte die am meisten gehandelt wurden.

Gruß
Viva

[100MIO]

@MikkaS
Du hast die Abzocke noch nicht verstanden!Wenn einer gestern an der Nasdaq den Wert für 0,087$ gekauft hat und puscht ihn heute auf 0,11€,dann sind das satte 20% Gewinn!

Verstanden??

Grüße

[Miriana]

Ist doch positiv zu sehen !!!

Also besteht doch reges Kauf/Verkaufinterresse !

Vieleicht kommt ja doch ne Neue Meldung ?

Warum sind denn auf einmal so viel mit dem Wert gehandelt ?

Eins steht fest der Ausschlag geht eindeutig Richtung Norden !

Gruß
Miri

[Viva-los-Tioz]

allgemein
Username: HAIRMAN2002
Registriert seit: 07.07.2002
User ist momentan: Online seit 06.12.2002 09:32:03
Threads: 188
Postings: 1065
Interessen keine Angaben


Wow in 5 Monaten 188 Threads

[Lipser]

Ja, und alle sind inhaltslos!

Lipser

[Anderas]

Also ich habe vor ein paar tagen schon 100% damit gemacht
bin zu 0,19 raus und auf der Nasdaq zu 0,09 wieder
voll rein in letzter Zeit immer wieder ziemlich große Ordern im bid drin immer so ziemlich um die gleiche Zeit
kenne Smpx jetzt schon ca zwei Jahre damals in der Euro am sonntag und im bereich der Hörgeräte der renner mit super Zukunftsausichten sollte Jahre lange Forschung umsonst gewesen sein und keiner bereit sein zu Investtieren?
PS.macht euch nur lustig über meine Schreibfehler wer zu letzt lacht lacht ambesten
und @Hairmann2002 die Cpusoftware war das letzte mal auch net schlecht und wird bald wieder .....

[Viva-los-Tioz]

Das muß man aber sagen:


1. Heute starkes Kaufinteresse in Deutschland (hohes volumen)

2.Bid und Ask ziehen ab.

Berlin bid 0,09
ask 0,10


Frankfurt habe ich leider keine daten,wer welche hat könnte sie doch mal kurz reinstellen.

Gruß
Viva

[Miriana]

Trotzden sollte man vorsichtig sein

Ist wie gesagt ein sehr rikanter Wert !

Nur was zum Zocken *lol*

Steht in den USA vorbörslich im Plus

SMPX SC 8,458,054 0.0890 19:20:55.9 0 +0.0090 +11.25

[Viva-los-Tioz]

Habe jetzt auch Daten aus ffm



Brief: 0,13 (0) 11:38:22
Geld: 0,10 (0) 11:38:22
Eröffnung: 0,10
Tageshoch: 0,10
Tagestief: 0,10
Schluss: 0,095
52W Hoch: 1,17
52W Tief: 0,06
Letzte Kurse:
0,10 11:04:25 - -
0,10 10:32:32 - -
0,10 09:09:00 - -
- - - -
- - - -
Handelsvolumen: 6.000
Gehandelte Stück: 60.000

Die angeforderte Aktion wird ausgeführt.
Bitte warten Sie.

[Viva-los-Tioz]

@Hairman2002

#4

Ich warte immer noch auf eine Antwort.

[Anderas]

SAN JOSE, Calif., Oct 24, 2002 /PRNewswire-FirstCall via COMTEX/ --
Symphonix(R) Devices Inc. (Nasdaq: SMPX) -- developers of the world`s first
FDA-approved middle-ear implant for moderate to severe sensorineural hearing
loss -- today reported a net loss of $1.9 million, or $0.05 per share, for the
third quarter ended September 30, 2002, compared to $1.8 million, or $0.05 per
share, for the second quarter of 2002 and $3.8 million, or $0.11 per share, for
the third quarter of 2001.

Net loss for the nine months ended September 30, 2002 was $5.7 million, or $0.16
per share, compared to $13.7 million, or $0.54 per share, for the nine months
ended September 30, 2001. Revenue for the quarter was $0.4 million compared to
$0.5 million for the third quarter of 2001. Revenue for the nine months ended
September 30, 2002 was $1.4 million compared to $1.5 million for the nine months
ended September 30, 2001.

CEO Kirk Davis stated that several business and marketing initiatives are
underway to increase product adoption by audiologists, the key patient referral
source for the Vibrant(R) Soundbridge(R) technology.

"We have been introducing new programs and expanding others in a concerted
effort to address the key issues with regard to adoption of this new technology
for moderate to severe sensorineural hearing loss," stated Davis, "and Q3 marked
a time of progress toward achieving these goals."



Highlights of marketing successes in the third quarter include:



-- In an effort to simultaneously increase patient confidence and provide

audiologists with a personal "test drive" of the technology, Symphonix

introduced the Direct Drive Simulator -- a demonstration system that

allows patients to personally experience the benefits of the company`s

Vibrant Soundbridge implantable middle-ear hearing device before

surgery. After a successful beta test, the Direct Drive Simulator units

have just recently been widely distributed to otologist clinics

worldwide, further reinforcing the audiologist to otologist referral

relationship.

-- In support of the company`s continuing efforts to reinforce the safety

and effectiveness of the Vibrant Soundbridge technology, findings from

a long-term patient study were recently released. The findings by the

clinical investigators concluded that patients implanted with the

Vibrant Soundbridge technology over a five-year period found that it is

not only safe and effective long after initial activation, but also

reaffirmed the original, outstanding clinical trial results.

-- The company continues to gain acknowledgement by health insurance

companies for the benefits the Vibrant Soundbridge brings to their

members. Based on this momentum, the company has introduced an

insurance guarantee program in selected markets designed to increase

adoption by audiologists by removing the issue of price from the

patient`s decision-making process. With the ultimate goal to provide

the audiologist with a successful Vibrant Soundbridge patient referral,

Symphonix will help facilitate and streamline the process for patients

seeking insurance coverage.

Another key business objective is securing widespread adoption of the Vibrant
Soundbridge technology throughout the U.S. military. After a successful pilot
program and upon gaining reimbursement from the military effective October 1,
2002, the company is focusing on rolling out the Vibrant Soundbridge to military
hospitals that have otologists on staff. The company expects to see revenue
growth from this program in 2003.

In addition, Symphonix recently launched a pilot program with the Veterans
Administration (VA), where the first VA surgery of the Vibrant Soundbridge was
conducted at the VA Hospital in San Francisco, California, on September 17,
2002. The Veterans Administration represents ten percent of the total U.S.
hearing healthcare market, and the company expects additional surgeries to be
scheduled in the coming months as part of its planned expansion of the pilot
program within the Veterans Administration.

The Vibrant Soundbridge represents an innovative approach to hearing improvement
-- the first implantable middle ear hearing device. Unlike conventional acoustic
hearing aids, which increase the volume of sound that goes to the eardrum, the
Vibrant Soundbridge bypasses the ear canal and eardrum by directly vibrating the
small bones in the middle ear. Because of its design, no portion of the device
is placed in the ear canal itself. The Vibrant Soundbridge has been approved by
the FDA as a safe and effective treatment option for adults with moderate to
severe sensorineural hearing loss who desire an alternative to acoustic hearing
aids. Of the approximate 28 million Americans who suffer from hearing loss, 60
percent have moderate to severe hearing loss.

About Symphonix Devices, Inc.

Founded in 1994, Symphonix Devices Inc., is a hearing technology company
dedicated to providing a family of products to improve communication ability and
quality of life for the millions of hearing-impaired people limited by current
hearing solutions. Symphonix` Vibrant Soundbridge is a surgical implant designed
to work with the natural structures of the middle-ear to enhance hearing and
communication ability for people with hearing impairment. The device can be
implanted during a short, outpatient medical procedure. More information about
Symphonix Devices, Inc. can be found at www.symphonix.com or by calling
800-833-7733.

Statements made in the press release regarding the future performance of our
business, including our marketing initiatives, are "forward-looking statements"
and are subject to a number of uncertainties that could cause actual results to
differ materially from the statements made. Such risks and uncertainties
include, but are not limited to, the Company`s products failing to achieve
widespread market acceptance by otologists, audiologists and the hearing
impaired, including those in the military and Veterans Administration, and the
company`s products failing to obtain insurance reimbursement. Further
information on potential factors that could affect the Company`s financial
results is included in the Company`s Form 10-Q for the quarter ending June 30
2002, and Form 10-K for the 2001 fiscal year filed with the Securities and
Exchange Commission.

NOTE: Symphonix, Vibrant and Soundbridge are registered trademarks of Symphonix
Devices, Inc.



Summary Consolidated Financial Information

(Thousands, except per share amounts)



Statement of Operations Data

(Unaudited)



Quarter ended Nine months ended

September 30, September 30,

2002 2001 2002 2001





Revenue $404 $535 $1,397 $1,546



Expenses:

Cost of goods sold 420 1,342 1,289 3,665

Research & development 526 1,406 1,904 4,927

Selling, general

& administrative 1,365 1,817 4,337 7,318

Total costs and expenses 2,311 4,565 7,530 15,910

Operating loss (1,907) (4,030) (6,133) (14,364)

Interest income, net 31 242 384 656

Net loss $(1,876) $(3,788) $(5,749) $(13,708)



Basic and diluted

net loss per

common share $(0.05) $(0.11) $(0.16) $(0.54)



Number of shares used

in calculation of basic

and diluted net loss

per common share 35,803 33,399 35,710 25,190







Balance Sheet Data



September 30, December 31,

2002 2001

(Unaudited)



Cash and cash

equivalents,

restricted cash

and short-term

investments $4,581 $12,291

Total assets 6,843 15,155

Stockholders` equity 3,348 9,288





Make Your Opinion Count - Click Here

http://tbutton.prnewswire.com/prn/11690X24663767

SOURCE Symphonix Devices Inc.



CONTACT: media, Denise Apcar of Neale-May & Partners, [phone],

ext. 514, or [e-mail]; or investors, Terry Griffin, CFO of

Symphonix Devices Inc., [phone]



URL: http://www.symphonix.com

http://www.prnewswire.com

[Anderas]

Bid0.09 (25)Ask 0.105 (250) Vorbörslich Nasdaq

[Viva-los-Tioz]

@Anderas

Wo hast Du dir Kurse her?

Gruß
Viva

[JasminB]

Last: 0.083
Close: 0.083
High: 0.000
Low: 0.000
Open:
Change: +0.003
Volume: 170,300


Bid: 0.080
Ask: 0.090
Bid/Ask Size: 209,500 / 74,000
08:55:07 0.083 15600 Cincinnati
08:55:07 0.085 42300 Cincinnati
08:44:08 0.085 7600 Cincinnati
08:44:08 0.085 4500 Cincinnati
08:43:58 0.089 5000 Cincinnati
08:39:15 0.089 28400 Cincinnati
08:39:15 0.090 1700 Nasdaq Small Cap at Ask
08:37:18 0.089 5000 Cincinnati
08:36:10 0.090 2500 Nasdaq Small Cap at Ask
08:27:41 0.089 10000 Cincinnati

[Viva-los-Tioz]

ca.170000 Stk. wurden bis jetzt in Deutschland gehandelt,wann gab es so eine Stückzahl in der Vergangenheit.

[JasminB]

Frankfurt
Bid:0.090
Ask:0,095

[Viva-los-Tioz]

ffm

Brief: 0,10 (0) 14:55:25
Geld: 0,09 (0) 14:55:25
Eröffnung: 0,10
Tageshoch: 0,10
Tagestief: 0,10
Schluss: 0,095
52W Hoch: 1,17
52W Tief: 0,06
Letzte Kurse:
0,10 11:04:25 - -
0,10 10:32:32 - -
0,10 09:09:00 - -
- - - -
- - - -

[Viva-los-Tioz]

Berlin 0,08 bid
0,11 ask

[JasminB]

Last: 0.096
High: 0.096
Low: 0.080
Open: 0.090
Change: +0.016
Volume: 1,070,100


Bid: 0.090
Ask: 0.100
Bid/Ask Size: 167,700 / 99,900

09:47:04 0.096 2000 Nasdaq Small Cap
09:47:58 0.096 1000 Nasdaq Small Cap at Bid
09:47:58 0.090 1000 Nasdaq Small Cap at Bid
09:47:53 0.091 20000 Nasdaq Small Cap at Bid
09:47:53 0.090 6700 Nasdaq Small Cap at Bid
09:47:49 0.090 47300 Nasdaq Small Cap at Bid
09:47:49 0.090 25000 Nasdaq Small Cap at Bid
09:47:45 0.096 900 Nasdaq Small Cap
09:47:44 0.090 1000 Nasdaq Small Cap at Bid
09:46:39 0.090 400 Nasdaq Small Cap at Bid

[JasminB]

Berlin
Aktueller Kurs: 0,11 Datum: 06.12.2002
Differenz zum Vortag: +0,02 (+22,22%) Uhrzeit: 16:00


Brief: 0,12 (0) 16:00:40
Geld: 0,09 (0) 16:00:40

[Flickus]

@Viva-los-Tioz:
Bin ja ganz erstaunt, wieviele hier plötzlich im board auftauchen. Was tun wir, rein oder nicht rein oder halt warten*hmmm*?
Kannst Du nicht in die Zukunft schauen*schnief*?
nice weekend
Flickus

[gurazz]

hey leute, ich kenne diese aktie praktisch nicht. ist mir erst gestern aufgefallen! wäre dies ein gewagter kauf?

[piso]

Finger weg Zockeraktie
Die Leute hier im Thread haben keine Ahnung

[gurazz]

k aber die aktie pendelt zw. 0.08 und 0.1 , das wären satte 25prozent gewinn. so im tagestrade.

[Viva-los-Tioz]

@gurazz

Weche doppel ID bist Du denn

[Viva-los-Tioz]

Sorry gurazz ich meinte natürlich piso .

[gurazz]

@viva, wie meinst du das?

[gurazz]

k, np

[Viva-los-Tioz]

@Flickus

Du hast Post!

Gruß
Viva

[Viva-los-Tioz]

SYMPHONIX ANNOUNCES DISSOLUTION OF ITS BUSINESS

SAN JOSE, Calif. — November 14, 2002 — Symphonix Devices, Inc. (NASDAQ: SMPX) announced today that its Board of Directors has unanimously deemed advisable the dissolution of the company and approved a plan of complete liquidation and dissolution of its business. The Board of Directors made this decision after an unsuccessful process of pursuing various strategic alternatives, including potential partner arrangements and a sale of the company outright.

Kirk Davis, CEO and a Director of the company stated, "The slow market adoption of the Vibrant Soundbridge combined with the difficult current financing environment has led us to make this very difficult decision. However, upon careful consideration from our Directors, Officers and advisors, we believe that this action is in the best interests of our stockholders."

Symphonix expects to submit the plan of complete liquidation and dissolution of its business to stockholders for approval at a special meeting of the stockholders to be held on a future date to be set by the Board of Directors.



--------------------------------------------------------------------------------

Statements made in the press release regarding the dissolution of the Company are "forward looking statements" and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made. Such risks and uncertainties include but are not limited to a decision by the Company’s Board of Directors to pursue other alternatives, such as bankruptcy. Further information on potential factors that could affect the Company’s dissolution is included in the Company’s Form 10-Q for the quarter ended September 30, 2002 filed with the Securities and Exchange Commission.For more information, please contact:

Investor Contact:
Investor Relations
[phone] Customer Contact:
Customer Service
[phone] Media Contact:
Eric Gertsman
Neale-May & Partners
[phone] x502
[e-mail]

©2000 Symphonix Devices, Inc. All rights reserved.
Legal Notice | Trademarks & Patents | [e-mail]
Site Last Updated November 19, 2002

[Viva-los-Tioz]

#39

Dies nur noch einmal zu Verdeutlichung der Lage!

Sollte wirklich ein Investor interesse haben,ja dann wird es wohl seht interessant.


Gruß
Viva

Wünsche noch einen schönen Sonntag

[Viva-los-Tioz]

@Flickus

Du hast Post


Gruß
Viva

[oski]

Das Volumen ist stabil ich bin dabei,da wird noch was kommen

[Flickus]

@Viva-los-Tioz:
Du hast auch Post
Gruß
Flickus

[Viva-los-Tioz]

Sollten gute News kommen wird es hier richtig rund gehen.

[westfalica]

Es geht schon richtig los

SYMPHONIX DEVICES - Nasdaq National Market: SMPX

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
0.099 0.017 (20.73) N/A 0.098 (628.01) 0.10 (2,440.34) 12:47


ciao

Westfalica

[westfalica]

Schlafen hier alle ???

In USA 20% +++


Bei uns 20% minus

Sind 40% Unterschied ???

ciao
Westfalica

[Viva-los-Tioz]

@westfalica

[Viva-los-Tioz]

Diese Antwort bekam ich auf meine Frage wie es mit Symphonix weiter geht.

Hello. More information about the future of the company, stock, etc. will be released soon.

Eric

> ----------
> From: xxxxxxxxxx
> Sent: Sunday, December 8, 2002 5:15 AM
> To: Eric Gertsman
> Subject: Symphonix
>

[Viva-los-Tioz]

Wann können wir mit Infos rechnen?

[Viva-los-Tioz]

Smpx gestern Abend nachbörslich bei 0,11 cent

[Viva-los-Tioz]

SYMPHONIX DVCS (912376) Berliner Freiverkehr Aktien (1170)
Best Bid
Volumen Quote
5000 Euro 0.08

Kauf Orders
Überhang Limit
10000 0.06
- -
- -
- -
- -
Weitere: 0
Best Ask
Quote Volumen
0.13 5000 Euro

Verkauf Orders
Limit Überhang
0.13 12150
- -
- -
- -
- -
Weitere: 0

Letzter Preis
Zeit: 09:01
Preis: 0.12 b

Tag
Kurse: 1
Umsatz: 3500

[Viva-los-Tioz]

http://www.nasdaq.com/asp/quotes_news.asp?selected=SMPX&symb…

[westfalica]

SYMPHONIX DEVICES - Nasdaq National Market: SMPX

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
0.10 0.015 (17.65) 0.005 (5.26) 0.09 (300) 0.097 (22) 16:15

Wenn der Kurs jeden Tag so weiter zulegt, wird das ein Super Weihnachtsfest:

ciao
Westfalica

[Viva-los-Tioz]

Es sieht fast so aus als ob wir die 0,20 bald wieder sehen.

Und wenn dann die News kommt das Symphonix übernommen wird,ja dann

Auf steigende Kurs

Viva

[Viva-los-Tioz]

SYMPHONIX DEVICES - Nasdaq National Market: SMPX

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
0.098 0.003 (3.16) 0.002 (2.00) 0.095 (100) 0.098 (538.50) 16:12

--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
0.10 0.005 (5.26) 0.09 (999) 0.10 (999) 16:25
Day Volume Last Size Open High Low
6,602,190 4,400 0.09 0.10 0.08
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+-+ 1,110 5,948 1.2344 N/A
Prev Close VWAP Avg Day Vol
0.095 0.0899 6,988,000


Schönes Wochenende allen!

Gruß
Viva

[Viva-los-Tioz]

SMPX
Symphonix Devices, Inc. Nasdaq-SCM


Back to Headlines | Previous Story




Symphonix -2: Announced Dissolution Plan In November

WASHINGTON (Dow Jones)--Symphonix Devices Inc. (SMPX) said it expects that a distribution to shareholders after its dissolution would be 2 cents to 6 cents a share, according to a preliminary proxy filed with the Securities and Exchange Commission Thursday.
The hearing device company`s shareholders will vote on a plan to dissolve the company and liquidate its assets at a meeting scheduled for Jan. 23, 2003, in San Jose.

Symphonix said it`s evaluating the value of its assets such as inventory, property and equipment, but expects that on a liquidation basis they will fetch considerably less than the values recorded on the company`s balance sheet. The estimate of a 2 cents- to 6-cents-a share distribution could be lowered or eliminated if selling the assets takes too much time or liabilities are greater than expected.

Through Sept. 30, Symphonix had $4.6 million in cash and equivalents and its balance sheet liabilities were about $3.6 million, the filing said.

Symphonix announced in November that its board had voted to dissolve the company, after an investment bank it had hired in September failed to find a merger partner or buyer for the company.

Symphonix is based in San Jose.

-By Christopher Scinta, Dow Jones Newswires; 202-628-7699; chris.scinta@ dowjones.com




Dow Jones Newswires
12-19-02 1735ET

[Shimarcal]

@Viva-los-Tioz

Und was sagt Dir das ?

Shimarcal

[Viva-los-Tioz]

@Shimarcal

Leider nur Maschinenübersetzung aber ich denke man versteht trotzdem den Sinn.


SMPX
Symphonix Geräte, Inc. Nasdaq SCM


stützen zu Schlagzeilen | vorherige Geschichte




Symphonix -2: Kündigte Auflösungsplan in November

WASHINGTON (Dow Jones) an - Symphonix Geräte, die Inc. (SMPX) sagte, daß es erwartet, daß ein Vertrieb zu Aktionären, nachdem seine Auflösung würde, sind 2 Cents zu eine Aktie 6 Cents entsprechend einer mit der Wertpapier- und Tauschprovision Donnerstag gefeilten vorläufigen Vollmacht.
Die Aktionäre des Anhörungsgeräteunternehmens stimmen über einen Plan dafür ab, das Unternehmen aufzulösen und seine Vermögenswerte an einer für den 23. Jan 2003 geplanten Besprechung in San Jose zu liquidieren.

Symphonix sagte, daß es den Wert seiner Vermögenswerte wie Inventur, Eigenschaft und Ausrüstung beurteilt, aber erwartet, daß auf einer Liquidierungsbasis sie beträchtlich weniger als die Werte auf der Bilanz des Unternehmens aufnahmen holen. Die geschätzten Kosten einer 2 Cents-zu 6 Cents-ein Aktienvertrieb konnte gesenkt oder entfernt werden beim Verkaufen der Vermögenswerte, daß Einstellungen, die zuviel Zeit oder Passiva größer als sind, erwarteten.

Durch den 30. Sept Symphonix hatte $ 4,6 Millionen in Bargeld und Gegenwerten, und seine Bilanzpassiva waren über $ 3,6 Millionen, die Ablage sagte.

Symphonix kündigte im November an, den sein Ausschuß dafür gestimmt hatte, das Unternehmen aufzulösen, nachdem eine Investitionsbank, die sie im September eingestellt hatte, versäumte, einen Unternehmenszusammenschlußpartner oder Käufer für das Unternehmen zu finden.

Symphonix ist in San Jose.

-von Christopher Scinta, Dow Jones Newswires; 202-628-7699; [e-mail]




Dow Jones Newswires
19.12.2 1735 ET


Gruß
Viva

[Shimarcal]

Tja, das sieht irgendwie nicht gut aus. Im Amiland fast nur Verkäufer. Der Kurs knickt heute wahrscheinlich noch ein.
Vielleicht bei 3 cent ein Zock wert ?

Gruss
Shimarcal

[Shimarcal]

@Viva

Bist Du im Urlaub oder fassungslos ?

Shimarcal

[Viva-los-Tioz]

@Shimarcal

Hallo,

nein ich bin nicht im Urlaub(leider)!

Gruß
Viva

[westfalica]

Habe mich nochmals mit SMPX beschäftigt und habe noch einige Fragen.

Wenn ich die letzten Meldungen richtig verstanden habe, will das Unternehmen schließen.
Warum wurde kein Konkurs beantragt ??
Also ist die Firma momentan noch zahlungsfähig.
Das Produkt ist weltweit anerkannt und wird benötigt.

Die Firma Siemens hat die Vertriebsrechte für 5 Jahre in Europa aufgrund ihrer Aktienbeteiligung erworben.
In einer Stellungnahme sichert sie auch weiterhin die Versorgung der Patienten und Kliniken zu.

Wie soll das bei einer Produktionseinstellung funktionieren?

Wenn die Aktien keinen Wert für die Zukunft haben,wer kauft dann wie zum Beispiel gestern in USA ca.5 Millionen Stück.
Alles nur Zocker?

Würde gerne eure Meinungen und Perspektiven hören.

ciao

Westfalica

[westfalica]

Habe noch einen interessante Nachricht gefunden:

The hearing device company`s shareholders will vote on a plan to dissolve the company and liquidate its assets at a meeting scheduled for Jan. 23, 2003, in San Jose

Das bedeutet das am 23.1.03 eine Aktionärsversammlung stattfindet um über den Plan abzustimmen.

Ich kann mir nicht vorstellen das die Aktionäre dem Vorschlag zustimmen werden,da dieses nur mit grossen eigenen Verlusten möglich wäre.
Bei solch einem guten und anerkannten Produkt, muss es auch noch andere Möglichkeiten geben das Unternehmen weiter
fortbestehen zu lassen.

Ich bin mir ziemlich sicher , dass wir am 23.01.03 eine
Überraschung erleben werden.

ciao
Westfalica
N

[Viva-los-Tioz]

Hallo Westfalica,

#63

Das kann ich mir auch nicht vorstellen das sich die Aktionäre mit 2-6 cents pro Share abfinden lassen würden.

Gruß
Viva

[westfalica]

@Viva

Ich finde das Verhalten der Geschäftsführung auch sehr merkwürdig. Normalerweise würde man bei auftretenden Schwierigkeiten diese benennen und gleichzeitig Bemühungen zur Weiterführung des Unternehmens in Aussicht stellen.

Einfach die Absicht das Unternehmen zu schliessen bekanntgeben und keine weitere Versuche zur Rettung zu unternehmen.
Das ist kein normales Verhalten.
Da muss Absicht dahinterstecken. Aber warum ??

ciao
Westfalica

[Viva-los-Tioz]

@westfalica

Und wenn man bedenkt das alle News i.P. Produkt äußerst positiv waren.

Gruß
Viva

[Viva-los-Tioz]

Hier einige Antworten von Ärzten in Deutschland zu der Soundbridge von Symphonix.

Von: [e-mail]
Datum: Montag, 26. August 2002 10:33:03
An: xxx
Betreff: Re: Vibrant Soundbridge

Sehr geehrter Herr xxx, vielen Dank für Ihre Anfrage. Folgende Antworten kann ich Ihnen geben :
1. Erste OP in Wuppertal vor knapp 3 Jahren
2. Hier bisher drei Implantationen, zuvor große Erfahrungen in Hannover erworben.
3. OP Dauer 2 - 3 Stunden
4. Man ist eine Woche im Krankenhaus, dann nach 10 - 12 Tagen kommt man zum Fädenziehen. Weitere Kontrolle nach 8 Wochen vor der Prozessoranpassung
5. Keine Probleme mit der Verträglichkeit
6. Inklusive Implantat, OP und stationärem Aufenthalt muß man mit ungefähr 10 000 Euro rechnen (Implantat kostet dabei 5 250 Euro ohne Audioprozessor), wenn Sie alles privat bezahlen.
7. Einzelne Krankenkassen übernehmen je nach Situation einen Teil oder auch das Ganze. Das muß man vorher klären, je nach medizinsichem Befund.
Bei Interesse können Sie gerne in meine Sprechstunde zur Beratung kommen (Tel. [phone]).
Mit freundlichem Gruß Prof. Dr. Kempf





Von: Prof. Maurer
Datum: Montag, 26. August 2002 15:57:29
An: xxxx
Betreff: Re: Vibrant Soundbridge

Sehr geehrter xxxx,
wir haben vor vier Jahren erstmals ein Symphonix-Gerät implantiert, insgesamt bisher 8, aber wir implantierten auch andere teil-und vollimplantierbare Geräte. Unsere Erfahrungen und vor allem die unserer Patienten mit Symphonix sind insgesamt sehr erfreulich.

Die Operation dauert ca. 1,5- 2 Stunden. Die medizinische Nachbehandlung ist nicht sehr aufwendig. Das Gerät muß aber wie jedes Hörgerät angepaßt und auch später regelmäßig überprüft und nachgestellt werden (beim Hörgeräteakustiker). Mit der Verträglichkeit hat es bisher nie Probleme gegeben. Die Kasse prüft im Einzelfall, welche Kosten Sie übernehmen will. Wenn die Kasse nichts zahlt kommen alles in allem (Gerät, OP;Krankenhaus) ca. 10.000-12.000 Euro auf Sie zu. Gelegentlich finde ich auch noch weitere Möglichkeiten, die Finanzierung zu ermöglichen.

Bitte wenden Sie sich an mich wenn weiter Interesse besteht.

Mit freundlichen Grüssen

J. Maurer





Von: stkd.prof.deitmer
Datum: Montag, 26. August 2002 17:01:16
An: xxxx
Betreff: Soundbridge

Sehr geehrter Herr xxxx,
wir haben hier am Klinikum bisher eine Soundbridge implantiert, die gut
vertragen wurde




Von: Dr. med. Christof Harenberg
Datum: Montag, 26. August 2002 18:14:26
An: xxxx
Cc: `[e-mail]`
Betreff: Vibrant Soundbridge

Sehr geehrter Herr xxxx,

Ihre Mitteilung vom 23.08.02 haben wir erhalten.
Unsere Erfahrung mit der Vibrant Soundbridge teilen wir in unserer Klinik
mit den Erfahrungen der Wurzburger Universitatsklinik mit denen wir im
engsten Kontakt stehen. Seit einigen Jahren werden dort Vibrant Soundbridge
Implantationen vorgenommen an denen wir mit einiger Regelma?igkeit
teilgenommen haben. Zu Beginn der Implantationen wurden die meisten Gerate
von der Firma Siemens-Symphonix gesponsert, soda? die Patienten keine
Kosten fur die Gerate zu tragen hatten. Das hat sich jetzt leider geandert,
soda? die Anzahl der Patienten im letzten Jahr deutlich zuruckgegangen ist.
In unserem Krankenhaus selbst haben wir im Januar diesen Jahres den ersten
Patienten implantiert. Weitere Patienten sind zur Zeit in der Warteschleife
und bemuhen sich noch um Finanzierung und Finanzierungsmoglichkeiten fur
die Operation und die Gerate.

Die Operationszeit muss mit 2 Stunden bis 2 1/2 Stunden gesetzt werden.
Der Eingriff erfolgt in Vollnarkose. Die stationare Behandlung wird 2 bis
3 Tage dauern.
Die medizinische Nachbehandlung von unserer Seite ist mit einigen Besuchen
vollig unproblematisch. Sehr viel aufwendiger ist nach sechs Wochen
postoperativ die Anpassung des Gerates durch den Horgerateakustiker, soda?
dieser Weg zum Horgerateakustiker der mit der Vibrant Soundbridge umgehen
kann und die entsprechende Software hat nicht so weit sein sollte.
Unvertraglichkeiten des implantierten Gerates sind bisher nicht bekannt.

Die Kosten fur die Implantation die wir als Pauschale anbieten wird bei ca.
12 000 Euro liegen. Bei anerkannten Berufs- oder Unfallversorgungsleiden
konnen die Kosten vollstandig von entsprechenden Stellen ubernommen werden.
Die Krankenkassen sind hinsichtlich der Kostenubernahme noch sehr
zuruckhaltend.

Uber unseren Akustiker ist unproblematisch auch ein Kontakt mit einem
Vibrant Soundbridgetrager herzustellen wobei Sie die Erfahrung machen
werden, da? sich das Horerlebnis mit einer Vibrant Soundbridge nicht mehr
mit einem knoventionellem Horgerat vergleichen lasst.

Mit freundl. Gruß

Dr. med. Harenberg



Gruß
Viva

[westfalica]

Auch von der Firma Siemens nur höchstes Lob.


In vielen klinischen Studien wurde die Sicherheit und Effektivität der Vibrant Soundbridge sowie die hohe Zufriedenheit der versorgten Patienten belegt.
Das System besteht aus einem langlebigen Implantat und einem stabilen externen Teil, der mit moderner Technik von Siemens ausgestattet ist. Sehr hohe Zufriedenheitswerte der Patienten zeichnen die Vibrant Soundbridge aus.

Wir möchten Sie darüber informieren, dass wir unsere langjährige Erfahrung mit der Vibrant Soundbridge zur kompetenten Betreuung der betroffenen Kliniken und Hörgeräteakustiker in Europa auch in Zukunft einsetzen werden.

Mit Ihren Fragen wenden Sie sich bitte an Ihren Klinikarzt bzw. Hörgeräteakustiker oder Audiologen. Selbstverständlich stehen wir Ihnen ebenfalls für Ihre Fragen zur Verfügung. Bitte kontaktieren Sie das Siemens/Symphonix Team oder rufen Sie uns an unter:

ciao
Westfalica

[Viva-los-Tioz]

@westfalica

#68

Hast Du die fehlende Telefonnummer?


Gruß
Viva

[westfalica]

Vorbörslicher Kurs in USA:
Symphonix Devices - Nasdaq National Market: SMPX

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
0.08 0.01 (14.29) 0.01 (14.29) 0.071 (90) 0.08 (1,736.56) 09:26

ciao
Westfalica

[westfalica]

@Viva

Telefon: +49 9131 / 308 - 3634
+49 9131 / 308 - 3412
+49 9131 / 308 - 3449
Fax: +49 9131 / 308 - 4915

ciao
Westfalica

[Viva-los-Tioz]

Danke Westfalica

Gruß
Viva

[aimster]

da ham sich die chefs schon ihren teil dabei gedacht...


Symphonix Announces Dissolution of Its Business


Symphonix Devices, Inc. announced today that its Board of Directors has unanimously deemed advisable the dissolution of the company and approved a plan of complete liquidation and dissolution of its business. The Board of Directors made this decision after an unsuccessful process of pursuing various strategic alternatives, including potential partner arrangements and a sale of the company outright.

Kirk Davis, CEO and a Director of the company stated, "The slow market adoption of the Vibrant Soundbridge combined with the difficult current financing environment has led us to make this very difficult decision. However, upon careful consideration from our Directors, Officers and advisors, we believe that this action is in the best interests of our stockholders."

Symphonix expects to submit the plan of complete liquidation and dissolution of its business to stockholders for approval at a special meeting of the stockholders to be held on a future date to be set by the Board of Directors.

Statements made in the press release regarding the dissolution of the Company are "forward-looking statements" and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made. Such risks and uncertainties include but are not limited to a decision by the Company``s Board of Directors to pursue other alternatives, such as bankruptcy. Further information on potential factors that could affect the Company``s dissolution is included in the Company``s Form 10-Q for the quarter ended September 30, 2002 filed with the Securities and Exchange Commission.

[aimster]

außerdem interessant für die die noch immer daran glauben dass SMPX nicht liquidiert wird dürfte dieser link sein:


http://www.hoergeraete-siemens.de/00_de/80_Presseforum/81_Pr…


siemens vertreibt die geräte in europa weiter, SMPX ist raus....siemens bruacht sie nicht mehr !

[Viva-los-Tioz]

Erlangen, 15. November 2002
Siemens sichert Nachsorge der europäischen Patienten mit dem implantierbaren
Hörsystem Vibrant Soundbridge auch nach Produktionseinstellung
des Gerätes durch den Hersteller Symphonix
Auch nach der Produktionseinstellung des implantierbaren Hörsystems Vibrant
Soundbridge durch den US-amerikanischen Hersteller Symphonix Devices wird
Siemens weiterhin die Nachsorge der betroffenen Patienten sichern. Aufgrund
nicht gewinnbringender Vermarktung des Gerätes auf dem amerikanischen Markt
gab Symphonix gestern bekannt, das Hörsystem nicht weiter produzieren zu können.
Die Siemens Audiologische Technik GmbH (SAT) ist seit Juni 2000 Vertriebspartner
von Symphonix in Europa. Zur Geschäftsaufgabe von Symphonix
stellte Dr. Roger Radke, Sprecher der Geschäftsführung von SAT, klar: „Das Wohl
der Patienten steht jetzt im Vordergrund. Siemens wird seine langjährige Kompetenz
auf diesem Gebiet auch nach der Geschäftsaufgabe des Herstellers den betroffenen
Kliniken und Hörgeräteakustikern in Europa zur Verfügung stellen und
damit für eine optimale Betreuung der Patienten sorgen.“
Die Vibrant Soundbridge wurde in 13 europäischen Ländern an insgesamt 97
Kliniken implantiert. Die klinische Erfahrung zeigt, dass Patienten mit dem implantierbaren
Hörsystem Vibrant Soundbridge langfristig sicher und effektiv versorgt
sind.
Siemens Medical Solutions (Med) ist weltweit einer der größten Anbieter im Gesundheitswesen.
Der Bereich steht für innovative Produkte, Dienstleistungen und Komplettlösungen. Abgedeckt wird
das gesamte Spektrum über bildgebende Systeme für Diagnose und Therapie, die Elektromedizin
und die Audiologie bis hin zu IT-Lösungen, die Arbeitsabläufe in Kliniken und Praxen optimieren
und zu einer höheren Effizienz führen. Zum Angebot gehört auch die Übernahme des Datenmanagements
beim Kunden als Application Service Provider bis hin zu an spezifischen Krankheitsbildern
ausgerichtetem Prozessmanagement in der Vorsorge, Heilung und Pflege. Med beschäftigt
weltweit rund 31 000 Mitarbeiter. Im Geschäftsjahr 2002 (30. September) erzielte Med nach vorläufiger
Rechnung einen Umsatz von 7,6 Mrd. € sowie einen Auftragseingang von 8,4 Mrd. €. Das
EBIT betrug 1 Mrd. €. Weitere Informationen unter: http://www.siemensmedical.com.
Press Presse Prensa



Siemens Audiologische Technik GmbH
Erika Weigmann
Gebbertstr. 125, 91058 Erlangen
Tel.: ++49-9131 308-3449, Fax: -3420
E-mail: [e-mail]
http:/www.hoergeraete-siemens.de
Informationsnummer: Med SAT 200207.042 d
Pressereferat Medical Solutions
Thorsten Opderbeck
Postfach 3260, 91050 Erlangen
Tel.: [phone]; Fax: -3047
E-mail: [e-mail]
Medical Solutions
Audiologie

[Viva-los-Tioz]

@aimster

#74

Dein link ist aus dem Jahr 2000 und da wird lediglich geschrieben das die Vermarktung der Soundbridge in Europa durch Siemens übernommen wird und das war damals doch positiv zu bewerten.

Gruß
Viva

[Viva-los-Tioz]

Symphonix hatte einen starken Partner gefunden der den Audio Processor zu der Soundbridge lieferte.


Super Produkt
Starker Partner
Sehr zufriedene Kunden
US Militär als Kunde
Ärzte konnten nur positives über die Soundbridge berichten



Ich kann mir nicht helfen aber ich habe irgendwie das Gefühl das da etwas faul ist.

[Viva-los-Tioz]

[Anderas]

Wollt eigentlich nur mal hören ob noch jemand da ist und wies eurer meinung nach mit SMPX weiter geht was wird z.b der 23.01.03 bringen wär net wen sich mal jemand meldet

[westfalica]

Hallo Anderas,

Ich rechne damit, dass der Kurs bis zum 23.1.03 noch mal anziehen wird.
Viele spekulieren aufgrund des guten Produktes darauf, dass es doch noch eine positive Überraschung geben wird.

Sollte das Unternehmen in irgendeiner Weise fortbestehen wird der Kurs explodieren.
Wenn nicht.., wird man den jetzigen niedrigen Kurs allemal
realisieren können.

ciao
Westfalica

[Instiktbroker]

...Hallo zusammen...

...dass wird der Renner für die Ohren...*ggg*
...die Sounbridge ist da wohl zu teuer und mittlerweile auch nicht mehr up to date...!!

hier spielt die Musik im Höhrgerätegeschäft...
Wunder der Woche 12.01.2003

Hilfe für´s Ohr - Neuer Mini-Hör-Computer für Schwerhörige

Mehr als 15 Millionen Menschen, also jeder sechste Deutsche, leidet unter Hörschäden. Jeder vierte Jugendliche ist betroffen, jeder dritte Erwachsene ab 40 Jahren und jeder zweite über 70. Trotzdem tragen nur rund 2,5 Millionen von ihnen ein Hörgerät – das sind knapp 17 Prozent der Betroffenen.

Im Gegensatz zur Brille, die seit längerem auch als modisches Accessoire anerkannt ist, hat das Hörgerät ein eher schlechtes Image – Schwerhörigkeit wird oft als peinlich empfunden. Dabei verschafft eine Hörhilfe vielen Menschen wieder Anschluss ans gesellschaftliche Leben.

Ein neuartiges, nahezu unsichtbares Im-Ohr-Hörgerät des Schweizer Herstellers Phonak soll nun dazu beitragen, dieses Vorurteil abzubauen und mehr Menschen mit Hörgeräten zu versorgen.
Claro CIC, so heißt das technische Wunderwerk, ist ein erstmals volldigitaler Hörcomputer von der Größe einer Erbse. Er findet vollständig im Gehörgang eines menschlichen Ohres Platz und ist deshalb von außen kaum zu sehen.

Um die Digitaltechnik auf so kleinem Raum unterzubringen, waren kleinere Strukturen (auf dem Mini-Chip sitzen 1,3 Millionen Transistoren), eine dichtere Bauweise (Phonak baut die Chips als erste Firma dreistöckig) und weniger Strombedarf der Elektronik (hier halfen die Entwicklungen von Swatch) Voraussetzung. Platz gespart wird auch dadurch, dass die Kontakte auf dem Chip nicht mehr verdrahtet, sondern mit modernster Flip-Chip-Technologie – nah verwandt zur Handy-Technologie – verbunden werden. So lässt sich wirklich jeder Kubikmillimeter Platz im Ohrkanal für eine ausgeklügelte Filter- und Verstärkertechnik ausnützen.

NemoTech – modernste Technologie für die Schalenfertigung

Das Ohr ist in seiner Form so einmalig wie ein Fingerabdruck. Um eine optimale Passform der Im-Ohr-Hörgeräte für jedes individuelle Ohr zu gewährleisten, entwickelte die Firma Phonak ein neues Verfahren für die Fertigung der Hörgeräteschalen.
Zuerst nimmt der Hörgeräte-Akustiker einen genauen Abdruck des Ohrkanals. Ein Laser tastet dann diesen Abdruck in drei Dimensionen exakt ab und übermittelt die Maße an einen PC. Dort wird dann die Passform auf die Geräteelektronik abgestimmt und ein virtuelles Schalenmodell für das Hörgerät erstellt. Schließlich wird aus einem Polymergranulat schichtenweise die Kunststoffschale gefertigt. Die fertige Schale wird zum Abschluss noch so nachbearbeitet, dass ihre Oberfläche hautverträglich wird.
Dank dieses modernen Schalen-Fertigungsverfahrens fügen sich Ohr und Hörgerät nahtlos ineinander – für Außenstehende kaum wahrnehmbar.

Gruß
Ins...broker

[Viva-los-Tioz]

@Anderas

Im schlimmsten Fall bekommst Du nur noch 2 Cent pro Share!


@instiktbroker


Das hört sich nicht schlecht an aber ich glaube das die Leute die in Smpx investiert sind (waren) erstmal die Sch....voll haben.

Gruß
Viva

[Instiktbroker]

@Viva-los-Tioz

...ist nun mal so ein ganz interessanter Wachstumsmarkt für die nächsten Jahre,...und das Produkt dieser Firma Phonak scheint meiner Meinung nach den Trend für die nächste Zeit zu setzten... ...ist leicht zu händeln und vor alllem nicht optisch auffällig und in der Pflege und Wartung mit wenig Kosten verbunden...! Zudem hat es einen relativ niedrigen Anschaffungspreis...!

..man wird sehen..
Gruß
Ins...broker

[Viva-los-Tioz]

Frankfurt SX6 EUR 0,060 0,030 - 0,030 - 50,00 270 9.000

Wer hat den da für 3Cent verkauft?
USA aktuell bei 0,0578

[Viva-los-Tioz]

Soll natürlich "denn" heißen.

Gruß
Viva

[Shimarcal]

@Viva-los-Tioz

Nasdaq -100 % ; Totalverlust ?????


Shimarcal

[Shimarcal]

#86 hat sich erledigt.

[Viva-los-Tioz]

Hallo Leute,

morgen ist es also soweit

Bin gespannt


Gruß
Viva

[Viva-los-Tioz]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934 (Amendment No. 1)

Filed by the Registrant x

Filed by a Party other than the Registrant ¨

Check the appropriate box:

x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
¨ Definitive Proxy Statement

¨ Definitive Additional Materials

¨ Soliciting Material Pursuant to §240.14a–12


SYMPHONIX DEVICES, INC.
(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

¨ No fee required.

x Fee computed on table below per Exchange Act Rules 14a–6(i)(4) and 0–11.


1) Title of each class of securities to which transaction applies: N/A

2) Aggregate number of securities to which transaction applies: N/A

3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0–11 (set forth the amount on which the filing fee is calculated and state how it is determined):

The fee is calculated at 1/50th of one percent of $2,300,000.00.

4) Proposed maximum aggregate value of transaction: $2,300,000.00

5) Total fee paid: $460.00


¨ Fee paid previously with preliminary materials.

¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0–11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.


1) Amount Previously Paid:

2) Form, Schedule or Registration Statement No.:

3) Filing Party:

4) Date Filed:



--------------------------------------------------------------------------------

[SYMPHONIX DEVICES LOGO]

SYMPHONIX DEVICES, INC.
2331 ZANKER ROAD
SAN JOSE, CALIFORNIA 95131-1107


--------------------------------------------------------------------------------


NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD ON JANUARY 31, 2003


--------------------------------------------------------------------------------


TO THE STOCKHOLDERS OF SYMPHONIX DEVICES, INC.:

NOTICE IS HEREBY GIVEN that a Special Meeting of Stockholders of Symphonix Devices, Inc., a Delaware corporation, will be held on January 31, 2003, at 9:00 a.m. local time, at our principal executive offices located at 2331 Zanker Road, San Jose, California 95131-1107, for the following purposes:

1. To ratify and approve the Plan of Complete Liquidation and Dissolution of Symphonix Devices, Inc., substantially in the form of Annex A attached to the accompanying Proxy Statement, including the liquidation and dissolution of Symphonix contemplated thereby.


2. To transact such other business as may properly come before the Special Meeting and any adjournments thereof.


The foregoing items of business are more fully described in the Proxy Statement accompanying this Notice.

Only stockholders of record at the close of business on December 2, 2002, the record date fixed by the Board of Directors, are entitled to notice of and to vote at the Special Meeting and any adjournment or postponement thereof.

By Order of the Board of Directors,


Kirk B. Davis
President and Chief Executive Officer

San Jose, California
January 21, 2003

YOUR VOTE IS IMPORTANT

ALL STOCKHOLDERS ARE CORDIALLY INVITED TO ATTEND THE SPECIAL MEETING. HOWEVER, TO ENSURE YOUR REPRESENTATION AT THE SPECIAL MEETING, YOU ARE URGED TO VOTE BY MARKING, SIGNING, DATING AND RETURNING THE ENCLOSED PROXY CARD AS PROMPTLY AS POSSIBLE IN THE ENCLOSED ENVELOPE, WHICH REQUIRES NO POSTAGE IF MAILED IN THE UNITED STATES. IF YOU ATTEND THE SPECIAL MEETING, YOU MAY CHOOSE TO VOTE IN PERSON EVEN IF YOU HAVE PREVIOUSLY SENT IN YOUR PROXY CARD.


--------------------------------------------------------------------------------

QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING

Q: What proposals will be voted on at the Special Meeting?


A: The following proposal will be voted on at the Special Meeting:


• The proposal to be voted on is whether to ratify and approve the Plan of Complete Liquidation and Dissolution of Symphonix Devices, Inc., referred to as “the plan of dissolution,” substantially in the form of Annex A attached to the accompanying Proxy Statement, including the liquidation and dissolution of Symphonix contemplated thereby.


Q: What will happen if the plan of dissolution is ratified and approved?


A: If the plan of dissolution is ratified and approved, we will file a certificate to dissolve Symphonix with the Delaware Secretary of State, complete the liquidation of our remaining assets, satisfy our remaining obligations and make distributions to our stockholders of available liquidation proceeds. See “Proposal No. 1—To Ratify and Approve the Plan of Complete Liquidation and Dissolution—Principal Provisions of the Plan.”


Q: When will stockholders receive any payment from our liquidation?


A: Subject to stockholder ratification and approval of the plan of dissolution, we anticipate that an initial distribution of liquidation proceeds will be made to our stockholders sometime in 2003. Thereafter, as we liquidate our remaining assets and properties we will distribute available liquidation proceeds, if any, to stockholders as the Board of Directors deems appropriate. We anticipate that the majority of the remaining liquidation proceeds will be distributed over a period of three years in accordance with Delaware law. See “Proposal No. 1—To Ratify and Approve the Plan of Complete Liquidation and Dissolution—Liquidating Distributions; Nature; Amount; Timing.”


Q: What is the amount of the payment that stockholders will receive from our liquidation?


A: As of September 30, 2002, we had approximately $4.6 million of cash, restricted cash and cash equivalents and our total liabilities on our balance sheet were approximately $3.6 million. In addition to satisfying the liabilities on the balance sheet, we anticipate using cash in the next several months for a number of items, including, but not limited to, the following:


• Ongoing operating expenses


• Expenses incurred in connection with extending our directors’ and officers’ insurance coverage


• Expenses incurred in connection with the liquidation


• Employee severance and related costs


• Customer service obligations


• Professional, legal and accounting fees


We are currently evaluating the market value of our other assets, including inventory and property and equipment, on a liquidation basis, but sales proceeds may be significantly lower than amounts recorded on the balance sheet as of September 30, 2002.

We currently estimate that the amount ultimately distributed to our stockholders would be in the range of $0.00 to $0.06 per share. See “Proposal No. 1—To Ratify and Approve the Plan of Complete Liquidation and Dissolution—General.”

1


--------------------------------------------------------------------------------


Q: What do I need to do now?


A: After carefully reading and considering the information contained in this Proxy Statement, you should complete and sign your proxy and return it in the enclosed return envelope as soon as possible so that your shares may be represented at the meeting. A majority of shares entitled to vote must be represented at the meeting to enable Symphonix to conduct business at the meeting. See “Information Concerning Solicitation and Voting.”


Q: Can I change my vote after I have mailed my signed proxy?


A: Yes. You can change your vote at any time before proxies are voted at the meeting. You can change your vote in one of three ways. First, you can send a written notice via registered mail to our President and Chief Executive Officer, Kirk B. Davis, at our executive offices, stating that you would like to revoke your proxy. Second, you can complete and submit a new proxy. If you choose either of these two methods, you must submit the notice of revocation or the new proxy to us. Third, you can attend the meeting and vote in person. See “Information Concerning Solicitation and Voting.”


Q: If my Symphonix shares are held in “street name” by my broker, will the broker vote the shares on my behalf?


A: A broker will vote Symphonix shares only if the holder of these shares provides the broker with instructions on how to vote. Shares held in “street name” by brokers or nominees who indicate on their proxies that they do not have discretionary authority to vote such shares as to a particular matter, referred to as “broker non-votes,” will not be voted in favor of such matter. The proposal to ratify and approve the plan of dissolution is a proposal that requires the affirmative vote of a majority of our outstanding shares to be approved by our stockholders. Accordingly, broker non-votes will have the effect of a vote against the proposal to ratify and approve the plan of dissolution. See “Information Concerning Solicitation and Voting—Quorum; Abstentions; Broker Non-Votes.”


Q: Can I still sell my shares of Symphonix common stock?


A: Yes. We expect that our common stock will continue to be listed on the Nasdaq SmallCap Market prior to the Special Meeting. However, we anticipate that we will request that our common stock be delisted from the Nasdaq SmallCap Market immediately prior to the filing of the Certificate of Dissolution with the Delaware Secretary of State, which (subject to stockholder ratification and approval of the plan of dissolution) we anticipate will occur on or around February 3, 2003. In addition, we will close our stock transfer books and discontinue recording transfers of shares of our common stock at the close of business on the date we file the Certificate of Dissolution with the Delaware Secretary of State. Thereafter, certificates representing shares of our common stock will not be assignable or transferable on our books except by will, intestate succession or operation of law. See “Proposal No. 1—To Ratify and Approve the Plan of Complete Liquidation and Dissolution—Listing and Trading of the Common Stock and Interests in the Liquidating Trust or Trusts.”


Q: Who can help answer my questions?


A: If you have any questions about the Special Meeting or the proposal to be voted on at the Special Meeting, or if you need additional copies of this Proxy Statement or copies of any of our public filings referred to in this Proxy Statement, you should contact our Investor Relations department at [phone]. Our public filings can also be accessed at the Securities and Exchange Commission’s web site at www.sec.gov.


2


--------------------------------------------------------------------------------

SYMPHONIX DEVICES, INC.
2331 ZANKER ROAD
SAN JOSE, CALIFORNIA 95131


--------------------------------------------------------------------------------


PROXY STATEMENT


--------------------------------------------------------------------------------


FOR THE SPECIAL MEETING OF STOCKHOLDERS

TO BE HELD ON JANUARY 31, 2003

Proxies in the form enclosed with this Proxy Statement are solicited by the Board of Directors of Symphonix Devices, Inc. for use at our Special Meeting of Stockholders to be held on January 31, 2003 at 9:00 a.m. local time, or at any adjournments or postponements thereof, for the purposes set forth in the accompanying Notice of Special Meeting of Stockholders. The Special Meeting will be held at our principal executive offices located at 2331 Zanker Road, San Jose, California 95131. Our telephone number at our principal executive offices is [phone].

These proxy solicitation materials were mailed on or about January 21, 2003 to all stockholders entitled to vote at the meeting.

INFORMATION CONCERNING SOLICITATION AND VOTING

Record Date and Voting Securities

Stockholders of record as of the record date, December 2, 2002, are entitled to notice of and to vote at the Special Meeting. As of the record date, 35,858,824 shares of our common stock were issued and outstanding, and no shares of our preferred stock were outstanding.

Revocability of Proxies

Execution of a proxy will not in any way affect a stockholder’s right to attend the Special Meeting and vote in person. Any stockholder giving a proxy has the right to revoke it by written notice delivered to our President and Chief Executive Officer, Kirk B. Davis at our principal executive offices at any time before it is exercised, or by voting in person at the Special Meeting. If a stockholder is not attending the Special Meeting, any proxy or notice should be returned in time for receipt no later than the close of business on the day preceding the Special Meeting.

Voting and Solicitation

Each share of common stock outstanding as of the record date will be entitled to one vote and stockholders may vote in person or by proxy. At the Special Meeting, a proposal to ratify and approve a plan of complete liquidation and dissolution of Symphonix, including the liquidation and dissolution of Symphonix contemplated thereby, will be presented. Our Board of Directors knows of no other matters to be presented at the Special Meeting. If any other matter should be presented at the Special Meeting upon which a vote may be properly taken, shares represented by all proxies received by the Board of Directors will be voted with respect thereto in accordance with the judgment of the persons named as attorneys in the proxies.

We will bear the cost of soliciting proxies. In addition, we may reimburse brokerage firms and other persons representing beneficial owners of shares for their expenses in forwarding solicitation material to such beneficial owners. Solicitation of proxies by mail may be supplemented by telephone, facsimile, e-mail or personal

3


--------------------------------------------------------------------------------

solicitation by our directors, officers or regular employees. We will not pay any additional compensation to such persons for such services. We have retained Georgeson Shareholder to assist in distribution of proxy materials and solicitation of votes. We will pay Georgeson Shareholder approximately $9,000 for its services, plus reimbursement for certain out-of-pocket expenses.

Quorum; Abstentions; Broker Non-Votes

The presence in person or by proxy of the holders of at least a majority of the outstanding shares of common stock entitled to vote at the Special Meeting is necessary to establish a quorum for the transaction of business. Votes cast by proxy or in person at the Special Meeting will be tabulated by the Inspector of Elections with the assistance of our transfer agent. The Inspector of Elections will also determine whether or not a quorum is present. Abstentions are included in the number of shares present or represented at the Special Meeting.

Shares held in “street name” by brokers or nominees who indicate on their proxies that they do not have discretionary authority to vote such shares as to a particular matter, referred to as “broker non-votes,” and shares which abstain from voting as to a particular matter, will not be voted in favor of such matter. The proposal to ratify and approve the plan of complete liquidation and dissolution is a proposal that requires the affirmative vote of a majority of our outstanding shares to be approved by our stockholders. Accordingly, abstentions and broker non-votes will have the effect of a vote against the proposal to ratify and approve the plan of complete liquidation and dissolution. Broker non-votes will be counted for purposes of determining the absence or presence of a quorum.

4


--------------------------------------------------------------------------------

CAUTION AGAINST FORWARD-LOOKING STATEMENTS

This Proxy Statement contains certain forward-looking statements, including statements concerning the value of our net assets, the anticipated liquidation value per share of common stock as compared to its market price absent the proposed liquidation, the timing and amounts of distributions of liquidation proceeds to stockholders, and the likelihood of stockholder value resulting from sale of certain of our significant assets. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of invoking these safe harbor provisions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, or industry results, to differ materially from our expectations of future results, performance or achievements expressed or implied by such forward-looking statements. These risks include the risk that we may incur additional liabilities, that the sale of our non-cash assets could be lower than anticipated, and that the settlement of our liabilities could be higher than expected, all of which would substantially reduce the distribution to our stockholders. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot guarantee future events or results. Except as may be required under federal law, we undertake no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur.

5


--------------------------------------------------------------------------------

PROPOSAL NO. 1

TO RATIFY AND APPROVE THE PLAN OF
COMPLETE LIQUIDATION AND DISSOLUTION

General

Our Board of Directors is proposing the plan of dissolution for ratification and approval by our stockholders at the Special Meeting. The plan was approved by the Board of Directors, subject to stockholder approval, on November 13, 2002. A copy of the plan of dissolution is attached as Annex A to this Proxy Statement. Certain material features of the plan are summarized below. We encourage you to read the plan of dissolution in its entirety.

After ratification and approval of the plan of dissolution, our activities will be limited to:

• filing a Certificate of Dissolution with the Secretary of State of the State of Delaware and thereafter remaining in existence as a non-operating entity for three years;


• selling any of our remaining assets, including our intellectual property and other intangible assets;


• paying our creditors;


• terminating any of our remaining commercial agreements, relationships or outstanding obligations;


• continuing to honor certain obligations to customers;


• establishing a contingency reserve for payment of our expenses and liabilities;


• preparing to make distributions to our stockholders;


• complying with the Securities and Exchange Commission reporting requirements; and


• completing tax filings.


Ratification and approval of the plan of dissolution by a majority of our stockholders will constitute approval of these activities by us.

As of September 30, 2002, we had approximately $4.6 million of cash, restricted cash and cash equivalents and our total liabilities on our balance sheet were approximately $3.6 million. In addition to satisfying the liabilities on the balance sheet, we anticipate using cash in the next several months for a number of items, including, but not limited to, the following:

• ongoing operating expenses;


• expenses of approximately $475,000 incurred in connection with extending our directors’ and officers’ insurance coverage;


• expenses incurred in connection with the liquidation;


• employee severance and related costs;


• customer service obligations; and


• professional, legal and accounting fees.


We are currently evaluating the market value of our other assets, including inventory and property and equipment, on a liquidation basis, but sales proceeds may be significantly lower than amounts recorded on the balance sheet as of September 30, 2002.

We currently estimate that the amount ultimately distributed to our stockholders would be in the range of approximately $0.00 to $0.06 per share. The distribution to our stockholders may be reduced by additional

6


--------------------------------------------------------------------------------

liabilities we may incur, the ultimate settlement amounts of our liabilities and our failure to achieve significant value for our non-cash assets. See “Factors to be Considered by Stockholders in Deciding Whether to Ratify and Approve the Plan.”

Our Board of Directors may, at any time, turn our management over to a third party to complete the liquidation of our remaining assets and distribute the proceeds from the sale of assets to our stockholders pursuant to the plan of dissolution. This third-party management may be in the form of a liquidating trust, which, if adopted, would succeed to all of our assets, liabilities and obligations. Our Board of Directors may appoint one or more of its members, one or more of our officers or a third party to act as trustee or trustees of such liquidating trust. If, however, all of our assets are not distributed within three years after the date our Certificate of Dissolution is filed with the State of Delaware, we will transfer our remaining assets to a liquidating trust if we have not already done so. Your ratification and approval of the plan of dissolution will also constitute your approval of any appointment and compensation of such trustees.

During the liquidation of our assets, we may pay our officers, directors, employees, and agents, or any of them, compensation for services rendered in connection with the implementation of the plan of dissolution. Your ratification and approval of the plan of dissolution will constitute your approval of the payment of any such compensation.

The following resolution will be offered at the Special Meeting:

“RESOLVED, THAT THE PLAN OF COMPLETE LIQUIDATION AND DISSOLUTION BE RATIFIED AND APPROVED.”

Background and Reasons for the Plan of Dissolution

From September 6, 2002 through November 13, 2002 our Board of Directors held a total of 5 meetings to explore and discuss our strategic alternatives. On November 13, 2002, our Board of Directors deemed advisable the liquidation and dissolution of Symphonix and adopted the plan of dissolution subject to stockholder approval. In reaching this decision, our Board considered that we have been unable to grow our quarterly revenues in the eight quarters since we received Food and Drug Administration approval to market our product in the United States. Revenues have remained constant each quarter at around $500,000 per quarter. The Board noted that adoption by audiologists, the key referral source for patient flow for our product was slow and was likely to continue to be slow. The Board also noted that the price of our product and overall procedure continued to be a significant issue relative to market adoption and that insurance coverage on a broad basis was unlikely.

Prior to the Board’s November 13, 2002 decision to pursue the liquidation and dissolution of Symphonix, the Board pursued strategic partnership opportunities and equity financing opportunities. In September 2002, we engaged an investment bank to assist in identifying and evaluating strategic alternatives, including the sale or merger of Symphonix. Between September 2002 and November 2002, the investment bank contacted multiple prospective strategic investors and merger partners, both domestic and international. During this time, management and members of our Board of Directors also contacted multiple potential financial investors. We were unsuccessful in locating a third party willing to enter into either a financing arrangement or a strategic business combination with us. After a careful review, the Board of Directors concluded on November 13, 2002 that, in light of the extensive efforts to locate an investment or strategic partner for us by both the investment bank and our management, it was unlikely that a financing or an acquisition or merger opportunity would become available to us. The Board also considered that after having reduced our expenses, including personnel earlier in 2002, we would not be able to reduce expenses and personnel further and still be able to sell and market our product. The Board concluded that reducing expenses and continuing operations was not a viable option. The Board also considered filing for protection under the U.S. Bankruptcy Code, but believed that bankruptcy would likely result in higher transaction costs and longer delays before potential distributions to stockholders than a dissolution. The Board believed that, based on the above, it was appropriate to initiate the dissolution process as

7


--------------------------------------------------------------------------------

soon as possible to maximize any potential monies to be distributed to stockholders by minimizing any additional costs and liabilities incurred if we continued our operations.

For these reasons, the Board of Directors concluded that our liquidation and dissolution would have the highest probability of returning the greatest current value to our stockholders.

Factors to be Considered by Stockholders in Deciding Whether to Ratify and Approve the Plan

There are many factors that our stockholders should consider when deciding whether to vote to ratify and approve the plan of dissolution. Such factors include those risk factors set forth below.

We cannot assure you of the amount, if any, of any distribution to our stockholders under the plan of dissolution.

Liquidation and dissolution may not create value to our stockholders or result in any remaining capital for distribution to our stockholders. We cannot assure you of the precise nature and amount of any distribution to our stockholders pursuant to the plan of dissolution. Uncertainties as to the precise net value of our non-cash assets and the ultimate amount of our liabilities make it impracticable to predict the aggregate net value, if any, ultimately distributable to our stockholders. The actual nature and amount of all distributions will depend in part upon our ability to convert our remaining non-cash assets into cash. We may not be successful in selling our non-cash assets, in which case we may not generate meaningful cash, if any, to return to our stockholders.

The proceeds from any sales of our non-cash assets may be less than anticipated.

Sales of our non-cash assets will be made on terms approved by our Board of Directors and may be conducted by competitive bidding, public sales or privately negotiated sales. The prices at which we will be able to sell our various non-cash assets will depend largely on factors beyond our control, including, without limitation, the condition of financial markets, the availability of financing to prospective purchasers of the assets, regulatory approvals and public market perceptions. In addition, we may not obtain as high a price for a particular asset as we might secure if we were not in liquidation. Furthermore, many of our non-cash assets, particularly our intellectual property, will decline in value over time, and we may not be able to consummate the sale of these assets in time to generate meaningful value which could be returned to our stockholders.

We may not be able to settle all of our obligations to creditors.

We have current and future obligations to creditors. These include, without limitation, long-term contractual obligations associated with business agreements with customers, including certain product warranties, and other third parties. As part of the wind down process, we will attempt to settle our obligations with our creditors. We may not, however, succeed in doing so. If we cannot reach an agreement with a creditor concerning an obligation, that creditor may choose to bring a lawsuit against us. Any litigation could delay or even prevent us from completing the plan of dissolution. Moreover, amounts required to settle our obligations to creditors will reduce the amount of remaining capital available for distribution to stockholders.

We will continue to incur claims, liabilities and expenses which will reduce the amount available for distribution to stockholders.

Claims, liabilities and expenses from operations (such as operating costs, salaries, directors’ and officers’ insurance, payroll and local taxes, legal and accounting fees and miscellaneous office expenses) will continue to be incurred as we wind down. These expenses will reduce the amount of assets available for ultimate distribution to stockholders. If available cash and amounts received on the sale of non-cash assets are not adequate to provide for our obligations, liabilities, expenses and claims, we may not be able to distribute meaningful cash, or any cash at all, to our stockholders.

8


--------------------------------------------------------------------------------


Distribution of assets, if any, to our stockholders could be delayed.

Although our Board of Directors has not established a firm timetable for distributions to our stockholders, the Board of Directors intends, subject to contingencies inherent in winding down our business, to make such distributions as promptly as practicable. However, we are currently unable to predict the precise timing of any distribution pursuant to our wind down. The timing of distribution will depend on and could be delayed by, among other things, the timing of sales of our non-cash assets, claim settlements with creditors and the litigation matter described above. Additionally, a creditor could seek an injunction against the making of distributions to our stockholders on the ground that the amounts to be distributed were needed to provide for the payment of our liabilities and expenses. Any action of this type could delay or substantially diminish the amount available for distribution to our stockholders.

If we fail to create an adequate contingency reserve for payment of our expenses and liabilities, our stockholders could be held liable for payment to our creditors of each such stockholder’s pro rata share of amounts owed to creditors in excess of the contingency reserve, up to the amount actually distributed to such stockholder.

If the plan of dissolution is ratified and approved by our stockholders, we will file a Certificate of Dissolution with the State of Delaware dissolving Symphonix. Pursuant to the Delaware General Corporation Law, we will continue to exist for three years after the dissolution becomes effective or for such longer period as the Delaware Court of Chancery shall direct, for the purpose of prosecuting and defending suits against us and enabling us gradually to close our business, to dispose of our property, to discharge our liabilities and to distribute to our stockholders any remaining assets. Under the Delaware General Corporation Law, in the event we fail to create an adequate contingency reserve for payment of our expenses and liabilities during this three-year period, each stockholder could be held liable for payment to our creditors of such stockholder’s pro rata share of amounts owed to creditors in excess of the contingency reserve, up to the amount actually distributed to such stockholder.

However, the liability of any stockholder would be limited to the amounts previously received by such stockholder from us (and from any liquidating trust or trusts) in the dissolution. Accordingly, in such event a stockholder could be required to return all distributions previously made to such stockholder. In such event, a stockholder could receive nothing from us under the plan of dissolution. Moreover, in the event a stockholder has paid taxes on amounts previously received, a repayment of all or a portion of such amount could result in a stockholder incurring a net tax cost if the stockholder’s repayment of an amount previously distributed does not cause a commensurate reduction in taxes payable. There can be no assurance that the contingency reserve established by us will be adequate to cover any expenses and liabilities. See “Contingent Liabilities; Contingency Reserve; Liquidating Trust.”

Our stock transfer books will close on the date we file the Certificate of Dissolution with the Delaware Secretary of State, after which it will not be possible for stockholders to publicly trade our stock.

We intend to close our stock transfer books and discontinue recording transfers of our common stock at the close of business on the date we file the Certificate of Dissolution with the Delaware Secretary of State, referred to as the “final record date.” Thereafter, certificates representing our common stock shall not be assignable or transferable on our books except by will, intestate succession or operation of law. The proportionate interests of all of our stockholders shall be fixed on the basis of their respective stock holdings at the close of business on the final record date, and, after the final record date, any distributions made by us shall be made solely to the stockholders of record at the close of business on the final record date, except as may be necessary to reflect subsequent transfers recorded on our books as a result of any assignments by will, intestate succession or operation of law.

9


--------------------------------------------------------------------------------


We do not expect to recognize any material revenue following the announcement of our intent to wind down.

Except for revenue resulting from the sale of our remaining inventory, we do not expect to recognize much, if any, additional revenue. Furthermore, it may be difficult to collect receivables now that we have announced our intent to wind down.

We will continue to incur the expenses of complying with public company reporting requirements.

We have an obligation to continue to comply with the applicable reporting requirements of the Securities Exchange Act of 1934, as amended, referred to as the “Exchange Act,” even though compliance with such reporting requirements is economically burdensome. In order to curtail expenses, we intend to, after filing our Certificate of Dissolution, seek relief from the Securities and Exchange Commission from the reporting requirements under the Exchange Act. We anticipate that, if such relief were granted, we would continue to file current reports on Form 8-K to disclose material events relating to our liquidation and dissolution along with any other reports that the Securities and Exchange Commission might require. However, the Securities and Exchange Commission may not grant any such relief.

If we fail to retain the services of certain key personnel, the plan of dissolution may not succeed.

The success of the plan of dissolution depends in large part upon our ability to retain the services of certain of our current officers. The retention of Kirk B. Davis, Terence J. Griffin, Geoffrey R. Ball and certain other qualified personnel is particularly difficult under our current circumstances. Failure to retain these personnel could harm the implementation of the plan of dissolution. If we fail to retain these personnel, we will need to hire others to oversee our liquidation and dissolution, which could involve additional compensation expenses, if such other personnel are available at all. For this reason and others discussed below, we may provide retention incentives to certain executive officers, particularly Kirk B. Davis, our Chief Executive Officer, Terence J. Griffin, our Chief Financial Officer, and Geoffrey R. Ball, our Chief Technical Officer. See “—Possible Effects of the Ratification and Approval of the Plan upon Directors and Executive Officers.”

Our stockholders could vote against the plan of dissolution.

Our stockholders could vote against the plan of dissolution. If we do not obtain stockholder ratification and approval of the plan of dissolution, we would have to continue our business operations from a difficult position, in light of our announced intent to liquidate and dissolve. Among other things, a substantial majority of our employees will have been terminated, and customer relationships will have been severely strained. On November 14, 2002, we terminated all of our employees with the exception of our Chief Executive Officer, our Chief Financial Officer, our Chief Technical Officer, our Vice President of Clinical Affairs and our Controller. Prospective employees, customers and other third parties may refuse to form relationships or conduct business with us if they have no confidence in our future.

Possible Effects of the Ratification and Approval of the Plan upon Directors and Executive Officers

Following the filing of the Certificate of Dissolution with the Delaware Secretary of State, we will continue to indemnify each of our current and former directors and officers to the extent required under Delaware law or our Certificate of Incorporation and Bylaws as in effect immediately prior to the filing of the Certificate of Dissolution. In addition, we intend to maintain our current directors’ and officers’ insurance policy through February 2003 and to obtain runoff coverage for an additional six years.

The Board of Directors may confer other benefits or bonuses to our employees and officers in recognition of their services to us based on the performance of such employees and officers, including performance during our liquidation process. The Board intends to set aside up to $100,000 as a retention bonus pool for our remaining employees, including our Chief Financial Officer, our Chief Technical Officer, our Vice President of Clinical Affairs and our Controller. In addition, pursuant to terms of his offer letter, upon our dissolution our Chief

10


--------------------------------------------------------------------------------

Executive Officer is entitled to receive severance payments of approximately $450,000 - $500,000. Any severance payments will be offset against the principal and interest of approximately $275,000 owed by our Chief Executive Officer to us as of December 31, 2002 pursuant to a note payable.

As a result, our directors and executive officers generally could be more likely to vote to approve the plan of dissolution, including the liquidation and dissolution of Symphonix contemplated thereby, than our other stockholders.

Other than as set forth above, it is not currently anticipated that our liquidation will result in any material benefit to any of our executive officers or to directors who participated in the vote to adopt the plan of dissolution.

The plan of dissolution was adopted by the unanimous vote of the Board of Directors.

Principal Provisions of the Plan

We will distribute pro rata to our stockholders, in cash or in-kind, or sell or otherwise dispose of, all of our property and assets. The liquidation is expected to commence as soon as practicable after ratification and approval of the plan of dissolution by our stockholders, and to be concluded prior to the third anniversary thereof, or such later date as required by Delaware law, by a final liquidating distribution either directly to our stockholders or to one or more liquidating trusts. Any sales of our assets will be made in private or public transactions and on such terms as are approved by the Board of Directors. It is not anticipated that any further votes of our stockholders will be solicited with respect to the approval of the specific terms of any particular sales of assets approved by the Board of Directors.

The plan of dissolution provides that the Board of Directors will liquidate our assets in accordance with any applicable provision of the Delaware General Corporation Law, including Sections 280 and 281. Without limiting the flexibility of the Board of Directors, the Board of Directors may, at it option, instruct our officers to follow the procedures set forth in Sections 280 and 281 of the Delaware General Corporation Law which instruct such officers to:

• give notice of the dissolution to all persons having a claim against us and provide for the rejection of any such claims in accordance with Section 280 of the Delaware General Corporation Law;


• offer to any claimant on a contract whose claim is contingent, conditional or unmatured, security in an amount sufficient to provide compensation to the claimant if the claim matures, and petition the Delaware Court of Chancery to determine the amount and form of security sufficient to provide compensation to any such claimant who rejects such offer in accordance with Section 280 of the Delaware General Corporation Law;


• petition the Delaware Court of Chancery to determine the amount and form of security which would be reasonably likely to be sufficient to provide compensation for claims that are the subject of pending litigation against us, and claims that have not been made known to us at the time of dissolution, but are likely to arise or become known within five (5) years (or longer in the discretion of the Delaware Court of Chancery), each in accordance with Section 280 of the Delaware General Corporation Law;


• pay, or make adequate provision for payment of, all claims made against us and not rejected, including all expenses of the sale of assets and of the liquidation and dissolution provided for by the plan of dissolution in accordance with Section 280 of the Delaware General Corporation Law; and


• post all security offered and not rejected and all security ordered by the Delaware Court of Chancery in accordance with Section 280 of the Delaware General Corporation Law.


If deemed necessary by the Board of Directors for any reason, we may, from time to time, transfer any of our unsold assets to one or more trusts established for the benefit of our stockholders, which property would thereafter be sold or distributed on terms approved by its trustees. If all of our assets (other than the contingency reserve) are not sold or distributed prior to the third anniversary of the effectiveness of our dissolution, we will transfer in final distribution such remaining assets to a trust. The Board of Directors may also elect in its

11


--------------------------------------------------------------------------------

discretion to transfer the contingency reserve, if any, to such a trust. Any of such trusts are referred to in this Proxy Statement as “liquidating trusts.” Notwithstanding the foregoing, to the extent that a distribution or transfer of any asset cannot be effected without the consent of a governmental authority, no such distribution or transfer shall be effected without such consent. In the event of a transfer of assets to a liquidating trust, we would distribute, pro rata to the holders of its capital stock, beneficial interests in any such liquidating trust or trusts.

It is anticipated that the interests in any such trusts will not be transferable; therefore, although the recipients of the interests would be treated for tax purposes as having received their pro rata share of property transferred to the liquidating trust or trusts and will thereafter take into account for tax purposes their allocable portion of any income, gain or loss realized by such liquidating trust or trusts, the recipients of the interests will not realize the value thereof unless and until such liquidating trust or trusts distributes cash or other assets to them. The plan of dissolution authorizes the Board of Directors to appoint one or more individuals or entities to act as trustee or trustees of the liquidating trust or trusts and to cause us to enter into a liquidating trust agreement or agreements with such trustee or trustees on such terms and conditions as may be approved by the Board of Directors. Approval and ratification of the plan of dissolution also will constitute the approval by our stockholders of any such appointment and any liquidating trust agreement or agreements. For further information relating to liquidating trusts, the appointment of trustees and the liquidating trust agreements, reference is made to “Contingent Liabilities; Contingent Reserves; Liquidation Trust.”

After the final record date, we will not issue any new stock certificates, other than replacement certificates. Any person holding options, warrants or other rights to purchase preferred or common stock must exercise such instruments or rights prior to the final record date. See “Listing and Trading of the Common Stock and Interests in the Liquidation Trust or Trusts” and “Final Record Date” below.

Following ratification and approval of the plan of dissolution by our stockholders, a Certificate of Dissolution will be filed with the State of Delaware dissolving Symphonix. Our dissolution will become effective, in accordance with the Delaware General Corporation Law, upon proper filing of the Certificate of Dissolution with the Secretary of State or upon such later date as may be specified in the Certificate of Dissolution. Pursuant to the Delaware General Corporation Law, we will continue to exist for three years after the dissolution becomes effective or for such longer period as the Delaware Court of Chancery shall direct, for the purpose of prosecuting and defending suits, whether civil, criminal or administrative, by or against us, and enabling us gradually to settle and close our business, to dispose of and convey our property, to discharge our liabilities and to distribute to our stockholders any remaining assets, but not for the purpose of continuing the business for which we were organized.

Abandonment; Amendment

Under the plan of dissolution, the Board of Directors may modify, amend or abandon the plan, notwithstanding stockholder ratification and approval, to the extent permitted by the Delaware General Corporation Law. We will not amend or modify the plan of dissolution under circumstances that would require additional stockholder solicitations under the Delaware General Corporation Law or the Federal securities laws without complying with the Delaware General Corporation Law and the Federal securities laws.

Liquidating Distributions; Nature; Amount; Timing

Although the Board of Directors has not established a firm timetable for distributions to stockholders if the plan of dissolution is ratified and approved by the stockholders, the Board of Directors intends, subject to contingencies inherent in winding up our business, to make such distributions as promptly as practicable. The liquidation is expected to be concluded prior to the third anniversary of the filing of the Certificate of Dissolution in Delaware by a final liquidating distribution either directly to our stockholders or to a liquidating trust. The proportionate interests of all of our stockholders shall be fixed on the basis of their respective stock holdings at the close of business on the final record date, and after such date, any distributions made by us shall be made

12


--------------------------------------------------------------------------------

solely to stockholders of record on the close of business on the final record date, except to reflect permitted transfers. The Board of Directors is, however, currently unable to predict the precise nature, amount or timing of this distribution or any other distributions pursuant to the plan of dissolution. The actual nature, amount and timing of all distributions will be determined by the Board of Directors, in its sole discretion, and will depend in part upon our ability to convert our remaining assets into cash and pay and settle our significant remaining liabilities and obligations. See “Factors to be Considered by Stockholders in Deciding Whether to Ratify and Approve the Plan.”

In lieu of satisfying all of our liabilities and obligations prior to making distributions to our stockholders, we may instead reserve assets deemed by management and the Board of Directors to be adequate to provide for such liabilities and obligations. See “Contingent Liabilities; Contingency Reserve; Liquidation Trust.”

Uncertainties as to the precise value of our non-cash assets and the ultimate amount of our liabilities make it impracticable to predict the aggregate net value ultimately distributable to stockholders. Claims, liabilities and expenses from operations (including operating costs, salaries, income taxes, payroll and local taxes, legal and accounting fees and miscellaneous office expenses), although currently declining, will continue to be incurred following stockholder ratification and approval of the plan of dissolution. These expenses will reduce the amount of assets available for ultimate distribution to stockholders, and, while a precise estimate of those expenses cannot currently be made, management and the Board of Directors believe that available cash and amounts received on the sale of assets will be adequate to provide for our obligations, liabilities, expenses and claims (including contingent liabilities) and to make cash distributions to stockholders. However, no assurances can be given that available cash and amounts received on the sale of assets will be adequate to provide for our obligations, liabilities, expenses and claims and to make cash distributions to stockholders. If such available cash and amounts received on the sale of assets are not adequate to provide for our obligations, liabilities, expenses and claims, distributions of cash and other assets to our stockholders will be reduced and could be eliminated. See “Factors to be Considered by Stockholders in Deciding Whether to Ratify and Approve the Plan.”

13


--------------------------------------------------------------------------------


Notwithstanding the above, following is a table showing management’s best estimate of cash proceeds and outlays and of our ultimate distribution to stockholders. The following estimates are not guarantees and they do not reflect the total range of possible outcomes. See “Factors to be Considered by Stockholders in Deciding Whether to Ratify and Approve the Plan” for a discussion of the risk factors related to the plan of dissolution and any potential proceeds which we may be able to distribute to stockholders.

Estimated Range of Distribution to Stockholders
(In millions except Shares Outstanding and per share Amounts)

Cash, Cash Equivalents and Restricted Cash as of September 30, 2002 $ 4.6 $ 4.6

Estimated Range: Cash Proceeds and Outlays
Operating cash use October 2002 through December 2002 $ (1.4 ) $ (1.4 )
Operating cash use January 2003 through March 2003 $ (0.5 ) $ (0.6 )
Accounts Receivable $ 0.2 $ 0.2
Inventory $ 0.0 $ 0.7
Property and Equipment $ 0.2 $ 0.8
Intellectual Property $ 0.7 $ 1.5
Note Payable to Bank $ (0.6 ) $ (0.6 )
Accounts Payable $ (0.3 ) $ (0.3 )
Accrued Compensation $ (0.7 ) $ (0.7 )
Revision SurgeryWarranty $ (0.3 ) $ (0.6 )
Professional Fees (Attorneys, Accountants, Trustee, Other) $ (0.6 ) $ (0.7 )
Directors and Officers Insurance $ (0.5 ) $ (0.5 )
Retention Bonus $ (0.1 ) $ (0.1 )
Termination of Marketing and Distribution Agreement $ (0.7 ) $ 0.0

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Estimated Range of Cash to Distribute to Stockholders $ 0.0 $ 2.3

Shares Outstanding as of December 2, 2002 35,858,824 35,858,824

Estimated Range of Per Share Distribution $ 0.00 $ 0.06


Sales of our Assets

The plan of dissolution contemplates the sale of all of our assets. Ratification and approval of the plan of dissolution will constitute approval, to the fullest extent permitted by law, by our stockholders of any such agreements and sales conducted by the Board of Directors or its appointed trustees. The plan of dissolution does not specify the manner in which we may sell our assets. Such sales could take the form of individual sales of assets, sales of groups of assets organized by business, type of asset or otherwise, a single sale of all or substantially all of our assets, or some other form of sale. Sales of our assets will be made on such terms as are approved by the Board of Directors in its sole discretion. The assets may be sold to one or more purchasers in one or more transactions over a period of time. We will not sell any of our assets to any of our “affiliates” without first obtaining the approval of any such asset sale by our stockholders, excluding the votes of any such affiliate and any other interested stockholder as determined by the Board of Directors in accordance with all applicable laws and regulations.

It is not anticipated that any further stockholder votes will be solicited with respect to the approval of the specific terms of any particular sales of assets approved by the Board of Directors. We do not anticipate amending or supplementing the Proxy Statement to reflect any such agreement or sale, unless required by applicable law. The prices at which we will be able to sell our various assets depends largely on factors beyond our control, including, without limitation, the condition of financial markets, the availability of financing to prospective purchasers of the assets, United States and foreign regulatory approvals, public market perceptions, and limitations on transferability of certain assets. In addition, we may not obtain as high a price for a particular asset as we might secure if we were not in liquidation.

14


--------------------------------------------------------------------------------


The Board of Directors intends to have several key executives continue to actively market our remaining assets. We believe that there may be two potential categories of buyers interested in purchasing our assets. One category of potential buyers may be interested in only purchasing our intellectual property and a second category may be interested in purchasing all of our assets including our intellectual property, inventory, property and equipment.

If we are successful in selling our intellectual property only, then we believe it is unlikely we will realize much, if any, value from the selling of our other assets such as inventory and property and equipment. In addition, with this type of transaction, we believe that we would need to set aside a reserve to pay product warranty claims, including claims involving customers who must have our product surgically removed.

We believe that a buyer who agrees to purchase substantially all of our remaining assets will value our inventory and property and equipment at closer to the value we have assigned to these assets in our financial statements. We also believe that this type of buyer may assume all product warranty obligations including any surgical removal costs.

We believe that we need to retain a small number of key employees through no later than March 2003 to best manage the asset sale process and other key milestones such as our annual audit, filing our Report on Form 10-K for the Fiscal Year Ended December 31, 2001 and filing our tax returns for the year ended December 31, 2002. We anticipate that the key employees will include our Chief Executive Officer, Kirk B. Davis, our Chief Financial Officer, Terence J. Griffin, our Chief Technical Officer, Geoffrey R. Ball, our Vice President of Clinical Affairs, Deborah Arthur and our Controller, Rodney Fuhriman. The Board of Directors believes at or around the time of the completion of the key milestones, it would be appropriate to appoint a trustee to manage the ongoing affairs of the Company. The Board of Directors intends to appoint a trustee no later than March 2003 to manage the Company’s affairs through the liquidation process. The duties of the trustee will include the distribution of any liquidating dividends to stockholders, the maintenance of shareholder records, responding to requests from the state of Delaware, handling any issues related to our contingent liabilities and other duties as may be needed.

Conduct of Symphonix Following Adoption of the Plan

Following ratification and approval of the plan of dissolution by our stockholders, our activities will be limited to distributing our assets in accordance with the plan, establishing a contingency reserve for payment of our expenses and liabilities, including liabilities incurred but not paid or settled prior to ratification of the plan of dissolution, selling any of our remaining assets, and terminating any of our remaining commercial agreements, relationships or outstanding obligations. Following the ratification and approval of the plan of dissolution by our stockholders, we shall continue to indemnify our officers, directors, employees and agents in accordance with our Certificate of Incorporation and Bylaws, including for actions taken in connection with the plan and the winding up of our affairs. Our obligation to indemnify such persons may be satisfied out of the assets of any liquidating trust. The Board of Directors and the trustees of any liquidating trust may obtain and maintain such insurance as may be necessary to cover our indemnification obligations under the plan of dissolution.

Reporting Requirements

Whether or not the plan of dissolution is ratified and approved, we have an obligation to continue to comply with the applicable reporting requirements of the Exchange Act, even though compliance with such reporting requirements is economically burdensome. If the plan of dissolution is ratified and approved, in order to curtail expenses, we will, after filing our Certificate of Dissolution, seek relief from the Securities and Exchange Commission from the reporting requirements under the Exchange Act. We anticipate that, if such relief is granted, we would continue to file current reports on Form 8-K to disclose material events relating to our liquidation and dissolution along with any other reports that the Securities and Exchange Commission might require.

15


--------------------------------------------------------------------------------


Contingent Liabilities; Contingency Reserve; Liquidating Trust

Under the Delaware General Corporation Law, we are required, in connection with our dissolution, to pay or provide for payment of all of our liabilities and obligations. Following the ratification and approval of the plan of dissolution by our stockholders, we will pay all expenses and fixed and other known liabilities, or set aside as a contingency reserve, cash and other assets which we believe to be adequate for payment thereof. We are currently unable to estimate with precision the amount of any contingency reserve which may be required, but any such amount (in addition to any cash contributed to a liquidating trust, if one is utilized) will be deducted before the determination of amounts available for distribution to stockholders.

The actual amount of the contingency reserve will be based upon estimates and opinions of management and the Board of Directors and derived from consultations with outside experts and review of our estimated operating expenses and future estimated liabilities, including, without limitation, anticipated compensation payments, product warranty obligations, estimated legal and accounting fees, operating lease expenses, payroll and other taxes payable, miscellaneous office expenses, expenses accrued in our financial statements, and reserves for litigation expenses. There can be no assurance that the contingency reserve in fact will be sufficient. We have not made any specific provision for an increase in the amount of the contingency reserve. Subsequent to the establishment of the contingency reserve, we will distribute to our stockholders any portions of the contingency reserve which we deem no longer to be required. After the liabilities, expenses and obligations for which the contingency reserve had been established have been satisfied in full, we will distribute to our stockholders any remaining portion of the contingency reserve.

If deemed necessary, appropriate or desirable by the Board of Directors for any reason, we may, from time to time, transfer any of our unsold assets to one or more liquidating trusts, or other structure we deem appropriate, established for the benefit of our stockholders, which property would thereafter be sold or distributed on terms approved by its trustees. The Board of Directors and management may determine to transfer assets to a liquidating trust in circumstances where the nature of an asset is not susceptible to distribution (for example, interests in intangibles) or where the Board of Directors determines that it would not be in the best interests of us and our stockholders for such assets to be distributed directly to the stockholders at such time. If all of our assets (other than the contingency reserve) are not sold or distributed prior to the third anniversary of the effectiveness of the dissolution, we must transfer in final distribution such remaining assets to a liquidating trust. The Board of Directors may also elect in its discretion to transfer the contingency reserve, if any, to such a liquidating trust.

The purpose of a liquidating trust would be to distribute such property or to sell such property on terms satisfactory to the liquidating trustees, and distribute the proceeds of such sale after paying our liabilities, if any, assumed by the trust, to our stockholders. Any liquidating trust acquiring all of our unsold assets will assume all of our liabilities and obligations and will be obligated to pay any of our expenses and liabilities which remain unsatisfied. If the contingency reserve transferred to the liquidating trust is exhausted, such expenses and liabilities will be satisfied out of the liquidating trust’s other unsold assets.

The plan of dissolution authorizes the Board of Directors to appoint one or more individuals or entities to act as trustee or trustees of the liquidating trust or trusts and to cause us to enter into a liquidating trust agreement or agreements with such trustee or trustees on such terms and conditions as may be approved by the Board of Directors. It is anticipated that the Board of Directors will select such trustee or trustees on the basis of the experience of such individual or entity in administering and disposing of assets and discharging liabilities of the kind to be held by the liquidating trust or trusts and the ability of such individual or entity to serve the best interests of our stockholders. Ratification and approval of the plan of dissolution by our stockholders will also constitute the approval by our stockholders of any such appointment and any liquidating trust agreement or agreements.

We may decide to use a liquidating trust or trusts, and the Board of Directors believes the flexibility provided by the plan of dissolution with respect to the liquidating trusts to be advisable. The trust would be

16


--------------------------------------------------------------------------------

evidenced by a trust agreement between us and the trustees. The purpose of the trust would be to serve as a temporary repository for the trust property prior to its disposition or distribution to our stockholders. The transfer to the trust and distribution of interests therein to our stockholders would enable us to divest ourselves of the trust property and permit our stockholders to enjoy the economic benefits of ownership thereof. Pursuant to the trust agreeme

[Anderas]

Falls noch jemand da is heute ist Hauptversammelung was meint ihr dazu eure meinugen?
Glaube immer noch an eine Ablehnung seitens der Anleger wen das passiert muß ein plan erstellt werden wieß weiter geht

[Wolframit]

und wurde jetzt auf der Hauptversammlung abgelehnt oder angenommen ?

[Viva-los-Tioz]

@alle

Versuche seid Tagen etwas über die HV zu finden aber man bekommt keine News was denn jetzt aus Smpx wird.

Gruß
Viva

[Anderas]

Mir gehts genauso weiß auch net was da läuft aber vieleicht versuchen die ja ein papiere einzusammeln
warum auch immer.
Anderer seits so schlecht kanns nicht gewesen sein sonst wäre der Kurs schon weiter runter höre mich weiter um ich selber verkaufe auf keinen fall

[Viva-los-Tioz]

@Anderas

Hopp oder Top

Gruß
Viva

[Anderas]

weiß jemand was da geht is im moment woll ausgesetzt
is woll eher hop als top

[Viva-los-Tioz]

Die Antwort habe ich heute auf meine Frage bekommen was auf der HV beschlossen wurde und warum man noch nichts darüber gehört hat.



You`re right, things are taking a bit longer than expected. I will keep you updated.

Eric



Gruß
Viva

[marathonmann]

[Viva-los-Tioz]

@Flickus

Du hast Post

[Viva-los-Tioz]

@alle

Gestern gingen 2 Trades in Berlin a 30k zu 6 cent weg.

Und was sieht man heute in den Staaten,da gingen schon über 6 Mio Stk bis jetzt!

[Viva-los-Tioz]

MED-EL TO PURCHASE SYMPHONIX ASSETS

SAN JOSE, Calif. -- March 21, 2003 -- Symphonix® Devices Inc.
(NASDAQ: SMPX) -- developers of the world`s first FDA-approved
middle-ear implant for moderate to severe sensorineural hearing
loss -- announced today that it has entered into a definitive
agreement with MED-EL, GmbH, a leading company in the field of
cochlear implants with headquarters in Innsbruck, Austria, under
which MED-EL has agreed to purchase certain assets and assume
certain liabilities of Symphonix.

Under the terms of the definitive asset purchase agreement,
MED-EL will pay $2.5 million to Symphonix in exchange for
ownership of certain Symphonix assets including inventory, property
& equipment and intellectual property and the assumption of all
patient-related liabilities, including the warranty of all Vibrant
Soundbridges currently in use. Geoff Ball, inventor of the Vibrant®
Soundbridge®, co-founder of Symphonix, and current Symphonix
Chief Technology Officer, will become MED-EL`s new middle-ear
implant Chief Technology Officer based out of the Innsbruck, Austria
worldwide headquarters. Deborah Arthur, Head of Clinical &
Regulatory Affairs for Symphonix will take on the same role for
MED-EL US at their Durham, North Carolina office.

The transaction is subject to the approval of Symphonix`
shareholders, as well as other customary conditions. Symphonix
expects the transaction to close in the second quarter of 2003.

The Vibrant Soundbridge product represents an innovative approach
to hearing improvement -- the first implantable middle ear hearing
device. Unlike conventional acoustic hearing aids, which increase
the volume of sound that goes to the eardrum, the Vibrant
Soundbridge bypasses the ear canal and eardrum by directly
vibrating the small bones in the middle ear. Because of its design,
no portion of the device is placed in the ear canal itself. The Vibrant
Soundbridge has been approved by the FDA as a safe and effective
treatment option for adults with moderate to severe sensorineural
hearing loss who desire an alternative to acoustic hearing aids.

About Symphonix Devices, Inc.
Symphonix Devices Inc., a hearing technology company in the
process of dissolution, had developed products to improve
communication ability and quality of life for the millions of hearing-
impaired people who were limited by current hearing solutions.
Symphonix` Vibrant Soundbridge is a surgical implant designed to
work with the natural structures of the middle-ear to enhance
hearing and communication ability for people with hearing
impairment. The device can be implanted during a short, outpatient
medical procedure. More information about Symphonix Devices,
Inc. and their dissolution can be found at www.symphonix.com.

About MED-EL
Over 25 years ago researchers who later founded MED-EL
developed one of the world`s first cochlear implants. Today,
MED-EL is growing faster than any other cochlear implant
company and is the global leader in innovative technology in the
field. MED-EL products are the result of collaborative efforts by
MED-EL engineers, surgeons, audiologists, therapists, and of
course, implant users.

MED-EL has their worldwide headquarters in Innsbruck, Austria,
a North American headquarters in Durham, North Carolina and
13 other subsidiaries worldwide. MED-EL has implanted their
devices in over 400 clinics, in 70 countries worldwide.


Statements made in the press release regarding the future
performance of our business, including the sale of our inventory,
property and equipment, intellectual property and patient related
liabilities to MED-EL are "forward looking statements" and are
subject to a number of uncertainties that could cause actual
results to differ materially from the statements made. Such risks
and uncertainties include, but are not limited to, the Company`s
shareholders not approving the complete liquidation and
dissolution of the company and the sale of the majority of the
company`s assets to MED-EL. Further information on potential
factors that could affect the Company`s financial results is
included in the Company`s Form 10-Q for the quarter ending
September 30 2002, and Form 10-K for the 2001 fiscal year
filed with the Securities and Exchange Commission.

Symphonix, Vibrant and Soundbridge are registered trademarks
of Symphonix Devices, Inc.


Media Contact:

Eric Gertsman
Neale-May & Partners
[phone] x502
[e-mail]

Investor Contact:

Terry Griffin, CFO
[phone]

[Viva-los-Tioz]

http://www.medel.com/welcome/medel_dt.html

[Viva-los-Tioz]

@Flickus

Du hast Post!


Gruß
Viva

[westfalica]

Latest News

--------------------------------------------------------------------------------
Symphonix Moves to the OTC Bulletin Board


SAN JOSE, Calif., Mar 25, 2003 /PRNewswire-FirstCall via COMTEX/ --
Symphonix(R) Devices Inc. (Nasdaq: SMPX) -- developers of the world`s first
FDA-approved middle-ear implant for moderate to severe sensorineural hearing
loss -- announced today that its common stock will be delisted from the Nasdaq
Market before the opening bell on March 28, 2003 and will commence trading that
same day on the Over-the-Counter Bulletin Board (OTCBB).

The decision by the Nasdaq Listing Qualifications Panel to delist Symphonix was
based on the company`s failure to meet Nasdaq`s minimum $1 bid price per share
requirement.

The OTCBB is a regulated quotation service that displays real-time quotes,
last-sale prices and volume information in over-the-counter equity securities.
OTCBB securities are traded by a community of market makers that enter quotes
and trade reports. The company`s common stock will trade under the ticker symbol
SMPX and can be viewed at www.otcbb.com.


ciao
Westfalica

[Big Charly]

Sehen wir geschädigten Aktionäre einen Teil von unserem Einsatz wieder????????????????????

Schönen abend
Big Charly

[Big Charly]

MED-EL to purchase Symphonix’ Assets

MED-EL announces the signature of an asset purchase agreement with Symphonix Inc, the Nasdaq listed Silicon Valley based developer of the world’s first US-FDA and CE-approved middle ear implant for moderate to severe sensorineural hearing loss with currently close to 1000 device users worldwide.

The agreement is contingent on Symphonix’ shareholders’ approval which is expected within 60 days. MED-EL will produce, further develop, market, and service the Vibrant Soundbridge.

The Vibrant® Soundbridge® product represents an innovative approach to hearing improvement – the first implantable middle ear hearing device. Unlike acoustic hearing aids, which increase the volume of sound that goes to the eardrum, the Vibrant Soundbridge bypasses the ear canal and eardrum by directly vibrating the small bones in the middle ear. Because of its design, no portion of the device is placed in the ear canal itself.

MED-EL is a leading company in the field of cochlear implants with its headquarters in Innsbruck, Austria, and through its technology leadership is the fastest growing cochlear implant company. An international team of 42 nationalities in 14 subsidiaries meets the needs of the deaf and hearing impaired in 70 countries worldwide. The newly founded company VIBRANT MED-EL will continue this commitment with the product Vibrant® Soundbridge®.

The goal of VIBRANT MED-EL and MED-EL will be the global distribution of the device and its further development. The inventor of the Vibrant Soundbridge, Geoffrey Ball, will be VIBRANT MED-EL’s chief technology officer.

After the completion of the transaction the customer service and marketing and sales activities will quickly commence mostly through the existing MED-EL distribution network. Because of the existing synergy potential a smooth and successful start can be expected. The teams of MED-EL and VIBRANT MED-EL are convinced of the future success of the most advanced, widespread and technologically leading middle-ear implant Vibrant® Soundbridge®.
Prof.US Ver. 20030330
© 2002 MED-EL


http://www.medel.com/professionals/us/medel_profus_blank.htm…


MED-EL Symphonix ` Aktiva zu kaufen

MED-EL verkündet die Unterschrift einer Vermögenswert-Ankauf-Zustimmung mit Symphonix Inc, der Nasdaq zählte auf, daß Silizium-Tal Entwickler von den ersten der Welt gründete, U.S.-FDA und CE-genehmigte mittleres Ohr, impfen Sie für ein, mäßigen Sie gegenwärtig weltweit zu strengem sensorineural-Gehör-Verlust mit in der Nähe von 1000 Gerät-Benutzern.

Die Zustimmung ist ` Zustimmung, die innerhalb 60 Tage erwartet wird, auf Symphonix ` Aktionären eventuell. MED-EL werden Sie produzieren, entwickeln Sie sich weiter, verkaufen Sie, und Dienst der Schwingende Soundbridge.

Der Vibrant® Soundbridge® Produkt stellt einen innovatorischen Ansatz zum Hören von Verbesserung dar–die ersten implantable mittleres Ohr-Gehör-Gerät. Anders als akustische Hörgeräte, die das Volumen von Klang, der zum Trommelfell geht, vergrößern, umfährt der Schwingende Soundbridge den Ohr-Kanal und das Trommelfell durch das Vibrieren der kleinen Knochen direkt im mittleren Ohr. Wegen seines Designs wird kein Teil des Gerätes in den Ohr-Kanal selbst gesetzt.

MED-EL ist eine führende Gesellschaft im Feld von cochlear-Implantaten mit seinem Hauptquartier in Innsbruck, Österreich, und durch seine Technologie-Führung ist, die schnellsten wachsend cochlear impfen Gesellschaft ein. Ein internationales Team von 42 Staatsangehörigkeiten in 14 Tochtergesellschaften entspricht den Bedürfnissen von das taub und Gehör beeinträchtigte weltweit in 70 Ländern. Die neu gegründete Gesellschaft SCHWINGEND MED-EL wird dieses Engagement mit dem Produkt Vibrant® Soundbridge® fortsetzen.

Das Ziel von SCHWINGEND MED-EL und MED-EL wird die globale Verteilung vom Gerät und seiner weiteren Entwicklung sein. Der Erfinder vom Schwingenden Soundbridge, Geoffrey Ball, wird SCHWINGEND sein MED-El Haupt Technologie-Offizier.

Nach der Vervollständigung der Verhandlung der Kundendienst und das Verkaufen und Verkäufe-Aktivitäten werden schnell meistens durch das Existieren beginnen MED-EL Verteilung-Netzwerk. Wegen des bestehenden synergy potentiell ein glatter und erfolgreicher Anfang kann erwartet werden. Die Teams von MED-EL und SCHWINGEND MED-EL wird vom künftigen Erfolg des anspruchsvollsten, weitverbreiteten und technologisch führenden mittler-Ohr-Implantates Vibrant® Soundbridge® überzeugt.
Prof.US Ver. 20030330

[Big Charly]

Schaut euch bitte den markierten Absatz einmal an

Am OTC-Bulletin-Board, das mit dem deutschen Telefonhandel vergleichbar ist, notieren zur Zeit etwa 20000 Werte von kleinen (Small Cabs) und kleinsten Unternehmen (Penny Stocks), von denen ca. 60 Prozent in den börsentäglich erscheinenden Pink Sheets gelistet werden. Die Pink Sheets sind dabei nichts weiter als ein internetgestützter Notierungsdienst, für den so gut wie keine Auflagen gelten.

Die am OTC-BB gelisteten Unternehmen unterliegen mittlerweile der Verpflichtung quartalsweise zu berichten, woraufhin rund 3000 Firmen ihre Aktien vom Handel zurückzogen, weil sie den Anforderungen nicht nachkommen konnten. Die Kurse solcher Unternehmen werden nun in den Pink Sheets veröffentlicht. Ansonsten sind Informationen nur über das Emissionsprospekt erhältlich, das zwar bei der SEC hinterlegt ist, aber dort nicht auf die inhaltliche Richtigkeit überprüft wird. Auch sonst unterliegen die am OTC-BB gelisteten Unternehmen keinen besonderen Zulassungsvoraussetzungen und auch im Regelfall nicht der Börsenüberwachung durch die SEC. Selbst ausländische Unternehmen, die nicht nach US-Vorschriften bilanzieren, können notiert werden.

Weitere Nachteile am OTC-BB

Weiterer Nachteil dieses Handelssegments ist die eingeschränkte Handelbarkeit. Der Tagesumsatz von Small Cabs oder Penny Stocks ist häufig so gering, daß ein Anleger tage- und wochenlang keinen Käufer findet. Zudem reagieren die gelisteten Aktien sehr empfindlich auf negative Informationen, wodurch Kursschwankungen von bis zu 80 Prozent an einem Tag keine Seltenheit sind.

Unternehmen, die in Penny Stocks emittieren und in den Pink Sheets gelistet werden, haben oft keine andere Möglichkeit der Kapitalbeschaffung. Sie erfüllen nicht einmal die minimalen Anforderungen des NASDAQ-Marktes. So kommt es nicht selten vor, daß sich in den Pink Sheets Unternehmen finden, die ihre Geschäftstätigkeit eingestellt haben, sich in Konkurs oder Liquidation befinden oder nur eine Briefkastenfirma sind.

Bei Werten auf den Pink Sheets stellt wie bei OTC-Titeln meist nur ein Marketmaker An- und Verkaufskurse. Die Differenz zwischen diesen beiden Preisen beträgt dabei aber nicht selten mehr als 100 Prozent. Die Chancen auf einen Gewinn schwinden bei diesen Spannen, unabhängig von der Unternehmensqualität, auf ein Minimum.


Aufgrund der hohen Anzahl schwarzer Schafe sind OTC- und Pink-Sheet-Aktien extrem riskant.

???????????????????????????????????????????????
Der Weg vom OTC-BB an die deutsche Börse!!!!!!!!!!!!!!!!
????????????????????????????????????????????????????

Der Initiator erwirbt am OTC-BB einen Firmenmantel, also ein Unternehmen das keinen Geschäftsbetrieb oder die Tätigkeit eingestellt hat, für einige Hunderttausend Dollar. Im Besitz nun nahezu aller Aktien des Unternehmens wird ein Geschäft, z.B. eine deutsche GmbH, eingebracht, woraufhin der Mehrheitsaktionär weitere Anteile erhält. Auf dem Markt wird dann ein großer Teil der noch im Streubesitz befindlichen Papiere aufgekauft. Die hohe Nachfrage bei gleichzeitig schwindendem Angebot ermöglicht den Kurs gezielt in die Höhe zu treiben. Unter Umständen entsteht so ein astronomischer Börsenwert, obwohl die Firma noch gar keinen oder nur sehr wenig Umsatz erzielt. Um die Aktien optisch billig erscheinen zu lassen, werden sie gesplittet.

Früher wurden die Papiere dann in den deutschen Freiverkehr eingeführt und mit dem Etikett "Neuemission" verkauft. Seit dem Herbst 1999 schieben zumindest die Regionalbörsen diesem Treiben einen Riegel vor. In Frankfurt hingegen werden weiterhin Titel des OTC-BB gehandelt. Somit steht den Finanzjongleuren auch weiterhin die Möglichkeit offen ahnungslose Anleger abzuzocken.

Könnte SYMPHONIX/MED-EL mit diesem Firmenmantel neubeginnen

Wie sehen dies die Symphonixaktionäre

Gruss

[otili]

In meinem Depot bei Entrium stehen meine Papiere nur noch mit Name und Stückzahl-kein Kurs, kein Wert-nix
Wieso das denn?

otili

[piso]

wer weiß ob sie noch gehandelt wird

[alanthegreenhorn]

VIBRANT MED-EL and MED-EL will distribute the device globally and continue its further development.
The existing structure of MED-EL subsidiaries will be responsible for sales and support of the Vibrant®
Soundbridge®.


Siemens Audiologische Technik has transferred its Vibrant® Soundbridge® European distribution rights
and responsibilities to VIBRANT MED-EL. Siemens’ advanced signal processing algorithms will remain
available for the Vibrant® Soundbridge® in the future.


Worldwide Headquarters:

VIBRANT MED-EL Hearing Technology GmbH
Fürstenweg 77
A-6020 Innsbruck
AUSTRIA
Tel: [phone]
Fax: [phone]
[e-mail]



To find your local MED-EL partners please refer to the MED-EL homepage www.medel.com

[piso]

was soll uns das sagen

[Viva-los-Tioz]

????

[Flickus]

Nix mehr los hier im thread, so wie scheinbar bei SMPX auch nicht :-((
Gruß an alle Symphoniker, who lost money.

[Viva-los-Tioz]

[otili]

So, die Hörgeräteepisode in meienem Depot ist beendet.
Heute kam der Ausbuchungsbescheid.

Sogar noch 3 Cent pro Aktie kassiert

Das war doch mal ein solides Investment
Mein Kaufpreis?



otili